

BioMed Realty Trust Inc
Form 10-Q
October 30, 2008

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**Form 10-Q
QUARTERLY REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2008.
Commission File Number: 1-32261
BIOMED REALTY TRUST, INC.
(Exact name of registrant as specified in its charter)**

Maryland
(State or other jurisdiction of
incorporation or organization)

20-1142292
(I.R.S. Employer
Identification No.)

**17190 Bernardo Center Drive
San Diego, California**
(Address of Principal Executive Offices)

92128
(Zip Code)

(858) 485-9840

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No

The number of outstanding shares of the registrant's common stock, par value \$0.01 per share, as of October 29, 2008 was 80,345,258.

BIOMED REALTY TRUST, INC.
FORM 10-Q QUARTERLY REPORT
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2008
TABLE OF CONTENTS

	Page
<u>PART I FINANCIAL INFORMATION</u>	
<u>Item 1 Consolidated Financial Statements</u>	3
<u>Consolidated Balance Sheets as of September 30, 2008 (Unaudited) and December 31, 2007</u>	3
<u>Consolidated Statements of Income for the three and nine months ended September 30, 2008 and 2007 (Unaudited)</u>	4
<u>Consolidated Statements of Cash Flows for the nine months ended September 30, 2008 and 2007 (Unaudited)</u>	5
<u>Notes to Consolidated Financial Statements (Unaudited)</u>	6
<u>Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	24
<u>Item 3 Quantitative and Qualitative Disclosures About Market Risk</u>	33
<u>Item 4 Controls and Procedures</u>	34
<u>PART II OTHER INFORMATION</u>	
<u>Item 1 Legal Proceedings</u>	35
<u>Item 1A Risk Factors</u>	35
<u>Item 2 Unregistered Sales of Equity Securities and Use of Proceeds</u>	35
<u>Item 3 Defaults Upon Senior Securities</u>	35
<u>Item 4 Submission of Matters to a Vote of Security Holders</u>	35
<u>Item 5 Other Information</u>	35
<u>Item 6 Exhibits</u>	36
<u>SIGNATURES</u>	37
<u>EX-3.1</u>	
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32.1</u>	

Table of Contents**PART I FINANCIAL INFORMATION****ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS**

**BIOMED REALTY TRUST, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)**

	September 30, 2008 (Unaudited)	December 31, 2007
ASSETS		
Investments in real estate, net	\$ 2,915,675	\$ 2,805,983
Investments in unconsolidated partnerships	20,296	22,588
Cash and cash equivalents	23,451	13,479
Restricted cash	8,291	8,867
Accounts receivable, net	7,284	4,457
Accrued straight-line rents, net	52,721	36,415
Acquired above-market leases, net	4,661	5,745
Deferred leasing costs, net	107,145	116,491
Deferred loan costs, net	12,057	15,567
Other assets	70,837	27,676
Total assets	\$ 3,222,418	\$ 3,057,268
LIABILITIES AND STOCKHOLDERS EQUITY		
Mortgage notes payable, net	\$ 354,828	\$ 379,680
Secured construction loan	500,998	425,160
Secured term loan	250,000	250,000
Exchangeable senior notes	175,000	175,000
Unsecured line of credit	266,660	270,947
Security deposits	7,469	7,090
Dividends and distributions payable	29,441	25,596
Accounts payable, accrued expenses, and other liabilities	106,553	95,871
Acquired below-market leases, net	19,212	23,708
Total liabilities	1,710,161	1,653,052
Minority interests	14,968	17,280
Stockholders' equity:		
Preferred stock, \$.01 par value, 15,000,000 shares authorized: 7.375% Series A cumulative redeemable preferred stock, \$230,000,000 liquidation preference (\$25.00 per share), 9,200,000 shares issued and outstanding at September 30, 2008 and December 31, 2007	222,413	222,413
Common stock, \$.01 par value, 100,000,000 shares authorized, 71,720,258 and 65,571,304 shares issued and outstanding at September 30, 2008 and December 31, 2007, respectively	717	656
Additional paid-in capital	1,432,350	1,277,770
Accumulated other comprehensive loss	(35,657)	(21,762)
Dividends in excess of earnings	(122,534)	(92,141)

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

Total stockholders' equity	1,497,289	1,386,936
Total liabilities and stockholders' equity	\$ 3,222,418	\$ 3,057,268

See accompanying notes to consolidated financial statements.

3

Table of Contents

BIOMED REALTY TRUST, INC.
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except share data)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2008	2007	2008	2007
	(Unaudited)		(Unaudited)	
Revenues:				
Rental	\$ 59,381	\$ 49,382	\$ 163,946	\$ 146,351
Tenant recoveries	20,911	15,084	53,297	47,264
Other income	519	366	1,697	8,445
Total revenues	80,811	64,832	218,940	202,060
Expenses:				
Rental operations	17,027	12,789	44,345	38,784
Real estate taxes	6,763	5,079	16,948	16,538
Depreciation and amortization	21,506	17,665	58,525	54,556
General and administrative	4,589	5,283	16,428	15,990
Total expenses	49,885	40,816	136,246	125,868
Income from operations	30,926	24,016	82,694	76,192
Equity in net loss of unconsolidated partnerships	(208)	(261)	(338)	(694)
Interest income	110	239	370	809
Interest expense	(13,035)	(7,043)	(28,600)	(21,013)
Income from continuing operations before minority interests	17,793	16,951	54,126	55,294
Minority interests in continuing operations of consolidated partnerships	(11)	51	(4)	(61)
Minority interests in continuing operations of operating partnership	(559)	(545)	(1,767)	(1,821)
Income from continuing operations	17,223	16,457	52,355	53,412
Income from discontinued operations before gain on sale of assets and minority interests				639
(Loss)/gain on sale of real estate assets		(1)		1,087
Minority interests attributable to discontinued operations				(74)
(Loss)/income from discontinued operations		(1)		1,652
Net income	17,223	16,456	52,355	55,064
Preferred stock dividends	(4,241)	(4,241)	(12,722)	(12,628)
	\$ 12,982	\$ 12,215	\$ 39,633	\$ 42,436

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

Net income available to common stockholders

Income from continuing operations per share available to common stockholders:

Basic and diluted earnings per share	\$	0.18	\$	0.19	\$	0.57	\$	0.62
--------------------------------------	----	------	----	------	----	------	----	------

Net income per share available to common stockholders:

Basic and diluted earnings per share	\$	0.18	\$	0.19	\$	0.57	\$	0.65
--------------------------------------	----	------	----	------	----	------	----	------

Weighted-average common shares outstanding:

Basic	71,513,333	65,308,702	68,995,015	65,300,802
-------	------------	------------	------------	------------

Diluted	74,714,841	68,274,908	72,120,329	68,262,086
---------	------------	------------	------------	------------

See accompanying notes to consolidated financial statements.

4

Table of Contents

BIOMED REALTY TRUST, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

	Nine Months Ended September 30,	
	2008	2007
	(Unaudited)	
Operating activities:		
Net income	\$ 52,355	\$ 55,064
Adjustments to reconcile net income to net cash provided by operating activities:		
Gain on sale of real estate asset		(1,087)
Depreciation and amortization, including amounts for discontinued operations	58,525	54,784
Minority interests in consolidated partnerships	4	61
Minority interests in operating partnership and discontinued operations	1,767	1,895
Allowance for doubtful accounts	104	281
Revenue reduction attributable to acquired above-market leases	1,084	1,857
Revenue recognized related to acquired below-market leases	(4,496)	(4,347)
Compensation expense related to restricted common stock and LTIP units	4,334	4,064
Amortization of deferred loan costs	2,837	2,278
Amortization of debt premium on mortgage notes payable	(886)	(596)
Loss from unconsolidated partnerships	338	694
Distributions representing return on capital from unconsolidated partnerships	627	328
Ineffectiveness recognized on interest rate swaps	727	
Distributions to minority interest in consolidated partnerships		(108)
Changes in operating assets and liabilities:		
Restricted cash	576	(3,577)
Accounts receivable	(2,931)	1,982
Accrued straight-line rents	(16,306)	(11,566)
Deferred leasing costs	(8,427)	(7,267)
Other assets	(6,292)	(3,971)
Security deposits	379	(164)
Accounts payable, accrued expenses and other liabilities	(2,503)	(7,450)
Net cash provided by operating activities	81,816	83,155
Investing activities:		
Purchases of interests in and additions to investments in real estate and related intangible assets	(176,108)	(313,081)
Distributions representing return of capital from unconsolidated partnerships	1,373	
Contributions to unconsolidated partnerships, net of intercompany eliminations	65	(20,327)
Proceeds from sale of real estate assets, net of selling costs		19,389
Minority interest investment in consolidated partnerships		205
Receipts of master lease payments	86	696
Additions to non-real estate assets	(7,790)	(307)
Funds held in escrow for acquisitions		(12,399)
Net cash used in investing activities	(182,374)	(325,824)

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

Financing activities:		
Proceeds from preferred stock offering		230,000
Payment of preferred stock offering costs		(7,587)
Proceeds from common stock offering	156,289	
Payment of common stock offering costs	(6,682)	
Payment of deferred loan costs	(140)	(3,809)
Unsecured line of credit proceeds	145,251	232,137
Unsecured line of credit repayments	(149,538)	(243,455)
Principal payments on mortgage notes payable	(23,244)	(4,547)
Secured construction loan proceeds	75,838	103,549
Deferred settlement payments, net on interest rate swaps	(4,823)	
Distributions to operating partnership unit and LTIP unit holders	(3,373)	(2,914)
Dividends paid to common stockholders	(66,326)	(59,558)
Dividends paid to preferred stockholders	(12,722)	(8,387)
Net cash provided by financing activities	110,530	235,429
Net increase/(decrease) in cash and cash equivalents	9,972	(7,240)
Cash and cash equivalents at beginning of period	13,479	25,664
Cash and cash equivalents at end of period	\$ 23,451	\$ 18,424
Supplemental disclosure of cash flow information:		
Cash paid during the period for interest (net of amounts capitalized of \$34,615 and \$40,642, respectively)	\$ 29,192	\$ 21,582
Supplemental disclosure of non-cash investing and financing activities:		
Accrual for preferred stock dividends declared	\$ 4,241	\$ 4,241
Accrual for common stock dividends declared	24,026	20,294
Accrual for distributions declared for operating partnership unit and LTIP unit holders	1,174	1,022
Accrued additions to real estate and related intangible assets	41,834	52,174

See accompanying notes to consolidated financial statements.

Table of Contents

**BIOMED REALTY TRUST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)**

1. Organization and Description of Business

BioMed Realty Trust, Inc., a Maryland corporation (the Company), was incorporated in Maryland on April 30, 2004. On August 11, 2004, the Company commenced operations after completing its initial public offering. The Company operates as a fully integrated, self-administered and self-managed real estate investment trust (REIT) focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry principally through its subsidiary, BioMed Realty, L.P., a Maryland limited partnership (the Operating Partnership). The Company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company's properties are generally located in markets with well-established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey.

2. Basis of Presentation and Summary of Significant Accounting Policies

The accompanying interim financial statements are unaudited, but have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in conjunction with the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all the disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments and eliminations, consisting of normal recurring adjustments necessary for a fair presentation of the financial statements for these interim periods have been recorded. These financial statements should be read in conjunction with the audited consolidated financial statements and notes therein included in the Company's annual report on Form 10-K for the year ended December 31, 2007.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, partnerships and limited liability companies it controls, and variable interest entities for which the Company has determined itself to be the primary beneficiary. All material intercompany transactions and balances have been eliminated. The Company consolidates entities the Company controls and records a minority interest for the portions not owned by the Company. Control is determined, where applicable, by the sufficiency of equity invested and the rights of the equity holders, and by the ownership of a majority of the voting interests, with consideration given to the existence of approval or veto rights granted to the minority shareholder. If the minority shareholder holds substantive participating rights, it overcomes the presumption of control by the majority voting interest holder. In contrast, if the minority shareholder simply holds protective rights (such as consent rights over certain actions), it does not overcome the presumption of control by the majority voting interest holder.

Investments in Partnerships

The Company evaluates its investments in limited liability companies and partnerships under Financial Accounting Standards Board (FASB) Interpretation No. 46 (revised December 2003), *Consolidation of Variable Interest Entities* (FIN 46R), an interpretation of Accounting Research Bulletin No. 51, *Consolidated Financial Statements*. FIN 46R provides guidance on the identification of entities for which control is achieved through means other than voting rights (variable interest entities) and the determination of which business enterprise should consolidate the variable interest entity (the primary beneficiary). Generally, FIN 46R applies when either (1) the equity investors (if any) lack one or more of the essential characteristics of a controlling financial interest, (2) the equity investment at risk is insufficient to finance that entity's activities without additional subordinated financial support or (3) the equity investors have voting rights that are not proportionate to their economic interests and the activities of the entity involve or are conducted on behalf of an investor with a disproportionately small voting interest.

If FIN 46R does not apply, the Company considers Emerging Issues Task Force (EITF) Issue No. 04-5, *Determining Whether a General Partner, or the General Partners as a Group, Controls a Limited Partnership or Similar Entity When the Limited Partners Have Certain Rights* (EITF 04-5), which provides guidance in determining whether a general partner controls a limited partnership. EITF 04-5 states that the general partner in a limited partnership is presumed to control that limited partnership. The presumption may be overcome if the limited partners

have either (1) the substantive ability to dissolve the limited partnership or otherwise remove the general partner without cause or (2) substantive participating rights, which provide the limited partners with the ability to effectively participate in significant decisions that would be expected to be made in the ordinary course of the limited partnership's business and thereby preclude the general partner from exercising unilateral control over the partnership. If the criteria in EITF 04-5 are met and the Company is the general partner or the managing member, as applicable, the consolidation of the partnership or limited liability company is required.

Table of Contents

Except for investments that are consolidated in accordance with FIN 46R or EITF 04-5, the Company accounts for investments in entities over which it exercises significant influence, but does not control, under the equity method of accounting. These investments are recorded initially at cost and subsequently adjusted for equity in earnings and cash contributions and distributions. Under the equity method of accounting, the Company's net equity in the investment is reflected in the consolidated balance sheets and its share of net income or loss is included in the Company's consolidated statements of income.

On a periodic basis, management assesses whether there are any indicators that the carrying value of the Company's investments in unconsolidated partnerships or limited liability companies may be impaired on a more than temporary basis. An investment is impaired only if management's estimate of the fair-value of the investment is less than the carrying value of the investment on a more than temporary basis. To the extent impairment has occurred, the loss is measured as the excess of the carrying value of the investment over the fair-value of the investment. Management does not believe that the value of any of the Company's unconsolidated investments in partnerships or limited liability companies was impaired as of September 30, 2008.

Investments in Real Estate

Investments in real estate, net consists of the following (in thousands):

	September 30, 2008	December 31, 2007
Land	\$ 390,685	\$ 313,685
Land under development	29,054	103,743
Buildings and improvements	2,137,926	1,675,530
Construction in progress	357,437	750,460
Tenant improvements	145,095	67,009
	3,060,197	2,910,427
Accumulated depreciation	(144,522)	(104,444)
	\$ 2,915,675	\$ 2,805,983

On October 3, 2008, a portion of the parking spaces at the garage located on the Company's Center for Life Science | Boston property was sold for approximately \$29.0 million pursuant to an agreement assumed by the Company in connection with its acquisition of the property in November 2006. The carrying value of the garage allocable to the portion that was sold is approximately \$29.0 million and has been recorded in other assets on the consolidated balance sheets as of September 30, 2008.

Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed

The Company reviews long-lived assets and certain identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The review of recoverability is based on an estimate of the future undiscounted cash flows (excluding interest charges) expected to result from the long-lived asset's use and eventual disposition. These cash flows consider factors such as expected future operating income, trends and prospects, as well as the effects of leasing demand, competition and other factors. If impairment exists due to the inability to recover the carrying value of a long-lived asset, an impairment loss is recorded to the extent that the carrying value exceeds the estimated fair-value of the property. The Company is required to make subjective assessments as to whether there are impairments in the values of its investments in long-lived assets. These assessments have a direct impact on the Company's net income because recording an impairment loss results in an immediate negative adjustment to net income. The evaluation of anticipated cash flows is highly subjective and is based in part on assumptions regarding future occupancy, rental rates and capital requirements that could differ materially from actual results in future periods. Although the Company's strategy is to hold its properties over the long-term, if the Company's strategy changes or market conditions otherwise dictate an earlier sale date, an impairment loss may be recognized to reduce the property to the lower of the carrying amount or

fair-value less costs to sell, and such loss could be material. If the Company determines that impairment has occurred, the affected assets must be reduced to their fair-value. As of and through September 30, 2008, no assets have been identified as impaired and no such impairment losses have been recognized.

Table of Contents**Deferred Leasing Costs**

Leasing commissions and other direct costs associated with new or renewal lease activity are recorded at cost and amortized on a straight-line basis over the terms of the respective leases, with remaining terms ranging from one month to approximately 16 years as of September 30, 2008. Deferred leasing costs also include the net carrying value of acquired in-place leases and acquired management agreements.

Deferred leasing costs, net at September 30, 2008 consisted of the following (in thousands):

	Balance at September 30, 2008	Accumulated Amortization	Net
Acquired in-place leases	\$ 168,391	\$ (86,893)	\$ 81,498
Acquired management agreements	12,921	(8,039)	4,882
Deferred leasing and other direct costs	23,909	(3,144)	20,765
	\$ 205,221	\$ (98,076)	\$ 107,145

Deferred leasing costs, net at December 31, 2007 consisted of the following (in thousands):

	Balance at December 31, 2007	Accumulated Amortization	Net
Acquired in-place leases	\$ 167,664	\$ (71,412)	\$ 96,252
Acquired management agreements	12,921	(6,603)	6,318
Deferred leasing and other direct costs	15,541	(1,620)	13,921
	\$ 196,126	\$ (79,635)	\$ 116,491

Revenue Recognition

The Company commences revenue recognition on its leases based on a number of factors. In most cases, revenue recognition under a lease begins when the lessee takes possession of or controls the physical use of the leased asset. Generally, this occurs on the lease commencement date. In determining what constitutes the leased asset, the Company evaluates whether the Company or the lessee is the owner, for accounting purposes, of the tenant improvements. If the Company is the owner, for accounting purposes, of the tenant improvements, then the leased asset is the finished space and revenue recognition begins when the lessee takes possession of the finished space, typically when the improvements are substantially complete. If the Company concludes that it is not the owner, for accounting purposes, of the tenant improvements (the lessee is the owner), then the leased asset is the unimproved space and any tenant improvement allowances funded under the lease are treated as lease incentives which reduce revenue recognized over the term of the lease. In these circumstances, the Company begins revenue recognition when the lessee takes possession of the unimproved space for the lessee to construct improvements. The determination of who is the owner, for accounting purposes, of the tenant improvements determines the nature of the leased asset and when revenue recognition under a lease begins. The Company considers a number of different factors to evaluate whether it or the lessee is the owner of the tenant improvements for accounting purposes. These factors include:

whether the lease stipulates how and on what a tenant improvement allowance may be spent;

whether the tenant or landlord retain legal title to the improvements;

the uniqueness of the improvements;

the expected economic life of the tenant improvements relative to the length of the lease;

the responsible party for construction cost overruns; and

who constructs or directs the construction of the improvements.

The determination of who owns the tenant improvements, for accounting purposes, is subject to significant judgment. In making that determination, the Company considers all of the above factors. However, no one factor is determinative in reaching a conclusion.

Table of Contents

All leases are classified as operating leases and minimum rents are recognized on a straight-line basis over the term of the related lease. The excess of rents recognized over amounts contractually due pursuant to the underlying leases are included in accrued straight-line rents on the accompanying consolidated balance sheets and contractually due but unpaid rents are included in accounts receivable. Existing leases at acquired properties are reviewed at the time of acquisition to determine if contractual rents are above or below current market rents for the acquired property. An identifiable lease intangible asset or liability is recorded based on the present value (using a discount rate that reflects the risks associated with the acquired leases) of the difference between (1) the contractual amounts to be paid pursuant to the in-place leases and (2) the Company's estimate of the fair market lease rates for the corresponding in-place leases at acquisition, measured over a period equal to the remaining non-cancelable term of the leases and any fixed rate renewal periods (based on the Company's assessment of the likelihood that the renewal periods will be exercised). The capitalized above-market lease values are amortized as a reduction of rental income over the remaining non-cancelable terms of the respective leases. The capitalized below-market lease values are amortized as an increase to rental income over the remaining non-cancelable terms of the respective leases and any fixed rate renewal periods, if applicable. If a tenant vacates its space prior to the contractual termination of the lease and no rental payments are being made on the lease, any unamortized balance of the related intangible will be written off.

Acquired above-market leases, net consisted of the following (in thousands):

	September 30, 2008	December 31, 2007
Acquired above-market leases	\$ 12,729	\$ 12,729
Accumulated amortization	(8,068)	(6,984)
	\$ 4,661	\$ 5,745

Acquired below-market leases, net consisted of the following (in thousands):

	September 30, 2008	December 31, 2007
Acquired below-market leases	\$ 37,961	\$ 37,961
Accumulated amortization	(18,749)	(14,253)
	\$ 19,212	\$ 23,708

Substantially all rental operations expenses, consisting of real estate taxes, insurance and common area maintenance costs are subject to recovery from tenants under the terms of lease agreements. Amounts recovered are dependent on several factors, including occupancy and lease terms. Revenues are recognized in the period the expenses are incurred. The reimbursements are recognized and presented in accordance with EITF 99-19, *Reporting Revenue Gross as a Principal versus Net as an Agent* (EITF 99-19). EITF 99-19 requires that these reimbursements be recorded gross, as the Company is generally the primary obligor with respect to purchasing goods and services from third-party suppliers, has discretion in selecting the supplier and bears the credit risk.

Lease termination fees are recognized when the related leases are canceled and the Company has no continuing obligation to provide services to such former tenants. A gain on early termination of leases of \$7.7 million for the nine months ended September 30, 2007 is included in other income in the 2007 consolidated statements of income. A portion of the related straight-line rent receivable and remaining other related intangible assets corresponding to the lease terminations was amortized in 2006 and approximately \$1.6 million was fully amortized in the nine months ended September 30, 2007.

Share-Based Payments

Statement of Financial Accounting Standards (SFAS) No. 123 (revised 2004), *Share-Based Payment*, requires that all share-based payments to employees be recognized in the income statement based on their fair-value. The fair-value is recorded based on the market value of the common stock on the grant date and is amortized to general and administrative expense and rental operations expense over the relevant service period, adjusted for anticipated forfeitures. Through the nine months ended September 30, 2008, the Company had only awarded restricted stock and long-term incentive plan (LTIP) unit grants under its incentive award plan (see Note 8), which are valued based on the closing market price of the underlying common stock on the date of grant, and had not granted any stock options.

Table of Contents***Assets and Liabilities Measured at Fair-Value***

On January 1, 2008, the Company adopted SFAS No. 157, *Fair Value Measurements* (SFAS 157), which defines fair-value, establishes a framework for measuring fair-value, and expands disclosures about fair-value measurements. SFAS 157 applies to reported balances that are required or permitted to be measured at fair-value under existing accounting pronouncements; accordingly, the standard does not require any new fair-value measurements of reported balances.

On January 1, 2008, the Company adopted SFAS No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities*, which permits companies to choose to measure certain financial instruments and other items at fair-value in order to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently. However, the Company has not elected to measure any additional financial instruments and other items at fair-value (other than those previously required under other GAAP rules or standards) under the provisions of this standard.

SFAS 157 emphasizes that fair-value is a market-based measurement, not an entity-specific measurement. Therefore, a fair-value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair-value measurements, SFAS 157 establishes a fair-value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity's own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair-value measurement is based on inputs from different levels of the fair-value hierarchy, the level in the fair-value hierarchy within which the entire fair-value measurement falls is based on the lowest level input that is significant to the fair-value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair-value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Currently, the Company uses forward starting and interest rate swaps to manage its interest rate risk. The valuation of these instruments is determined using widely accepted valuation techniques including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves. The fair-values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash receipts (or payments) and the discounted expected variable cash payments (or receipts). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. To comply with the provisions of SFAS 157, the Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty's nonperformance risk in the fair-value measurements. In adjusting the fair-value of its derivative contracts for the effect of nonperformance risk, the Company has considered the impact of netting and any applicable credit enhancements, such as collateral postings, thresholds, mutual puts, and guarantees.

Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair-value hierarchy, the credit valuation adjustments associated with its derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by itself and its counterparties. However, as of September 30, 2008, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivatives. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair-value hierarchy (see Note 12).

No other assets or liabilities are measured at fair-value on a recurring basis, or have been measured at fair-value on a non-recurring basis subsequent to initial recognition, in the accompanying consolidated balance sheets as of September 30, 2008.

Table of Contents***Derivative Instruments***

The Company records all derivatives on the consolidated balance sheet at fair-value. The accounting for changes in the fair-value of derivatives depends on the intended use of the derivative and the resulting designation. Derivatives used to hedge the exposure to changes in the fair-value of an asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair-value hedges. Derivatives used to hedge the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. In determining the fair-value of its derivatives, the Company considers the credit risk of its counterparties. These counterparties are generally larger financial institutions engaged in providing a variety of financial services. These institutions generally face similar risks regarding adverse changes in market and economic conditions, including, but not limited to, fluctuations in interest rates, exchange rates, equity and commodity prices and credit spreads. Recent disruptions in the financial markets have heightened the risks to these institutions.

For derivatives designated as cash flow hedges, the effective portion of changes in the fair-value of the derivative is initially reported in other comprehensive income (outside of earnings) and subsequently reclassified to earnings when the hedged transaction affects earnings. If charges relating to the hedged transaction are being deferred pursuant to redevelopment or development activities, the effective portion of changes in the fair-value of the derivative are also deferred in other comprehensive income on the consolidated balance sheet, and are amortized to the income statement once the deferred charges from the hedged transaction begin again to affect earnings. The ineffective portion of changes in the fair-value of the derivative is recognized directly in earnings. The Company assesses the effectiveness of each hedging relationship by comparing the changes in cash flows of the derivative hedging instrument with the changes in cash flows of the designated hedged item or transaction.

The Company's objective in using derivatives is to add stability to interest expense and to manage its exposure to interest rate movements or other identified risks. To accomplish this objective, the Company primarily uses interest rate swaps as part of its cash flow hedging strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts in exchange for fixed-rate payments over the life of the agreements without exchange of the underlying principal amount. During 2007 and the nine months ended September 30, 2008, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt and future variability in the interest-related cash flows from forecasted issuances of debt (see Notes 6 and 12). The Company formally documents the hedging relationships for all derivative instruments, accounts for all of its interest rate swap agreements as cash flow hedges, and does not use derivatives for trading or speculative purposes.

Management's Estimates

Management has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reporting of revenues and expenses during the reporting period to prepare these consolidated financial statements in conformity with GAAP. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates under different assumptions or conditions.

Segment Information

The Company's properties share the following similar economic and operating characteristics: (1) they have similar forecasted returns (measured by capitalization rate at acquisition), (2) they are generally occupied almost exclusively by life science tenants that are public companies, government agencies or their subsidiaries, (3) they are generally located near areas of high life science concentrations with similar demographics and site characteristics, (4) the majority of properties are designed specifically for life science tenants that require infrastructure improvements not generally found in standard properties, and (5) the associated leases are primarily triple-net leases, generally with a fixed rental rate and scheduled annual escalations, that provide for a recovery of close to 100% of operating expenses. Consequently, the Company's properties qualify for aggregation into one operating segment under the provisions of SFAS No. 131, *Disclosures about Segments of an Enterprise and Related Information*.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

Table of Contents**3. Minority Interests**

Minority interests on the consolidated balance sheets relate primarily to the partnership and LTIP units in the Operating Partnership (collectively, the Units) that are not owned by the Company. In conjunction with the formation of the Company, certain persons and entities contributing interests in properties to the Operating Partnership received partnership units. In addition, certain limited partners of the Operating Partnership have received LTIP units in connection with services rendered or to be rendered to the Operating Partnership. Limited partners who have been issued Units have the right to require the Operating Partnership to redeem part or all of their Units upon vesting of the Units, if applicable. The Company may elect to acquire those Units in exchange for shares of the Company's common stock on a one-for-one basis, subject to adjustment in the event of stock splits, stock dividends, issuance of stock rights, specified extraordinary distributions and similar events, or pay cash based upon the fair market value of an equivalent number of shares of the Company's common stock at the time of redemption. The value of the Units not owned by the Company, had such units been redeemed at September 30, 2008, was approximately \$93.0 million based on the average closing price of the Company's common stock of \$26.55 per share for the ten consecutive trading days immediately preceding September 30, 2008.

The following table shows the vested ownership interests in the Operating Partnership:

	September 30, 2008		December 31, 2007	
	Partnership Units and LTIP Units	Percentage of Total	Partnership Units and LTIP Units	Percentage of Total
BioMed Realty Trust	71,513,333	95.9%	65,308,702	95.7%
Minority interest consisting of:				
Partnership and LTIP units held by employees and related parties	2,887,644	3.9%	2,726,172	4.0%
Partnership units held by third parties	190,392	0.2%	190,392	0.3%
Total	74,591,369	100.0%	68,225,266	100.0%

The accompanying consolidated financial statements include the results of investments in four variable interest entities in which the Company was considered to be the primary beneficiary under FIN 46R for the periods presented. As of September 30, 2008, the Company had a 70% interest in the limited liability company that owns the 530 Fairview Avenue property and an 87.5% interest in the limited liability company that owns the Ardenwood Venture property. These entities are consolidated in the accompanying consolidated financial statements. Equity interests in these partnerships not owned by the Company are classified as minority interest on the consolidated balance sheets as of September 30, 2008. Subject to certain conditions, the Company and the holder of the minority interest in the Fairview limited liability company can purchase the other member's interests (put-call option) and the Company has the right to purchase the other member's interest or sell its own interest in the Ardenwood limited liability company (buy-sell option). The estimated fair-values of these options are not material and the Company believes that it will have adequate resources to settle the options if exercised.

On October 1, 2007, pursuant to the exercise of a put option by the minority interest limited partner in the limited partnership that owns the King of Prussia property, the Company completed the purchase of the remaining 11% interest in the limited partnership for consideration of approximately \$1.8 million, excluding closing costs. On June 2, 2008, pursuant to the exercise of a put option by the minority interest member, the Company completed the purchase of the remaining 30% interest in the limited liability company that owns the Waples Street property for consideration of approximately \$1.8 million, excluding closing costs. On October 14, 2008, the Company completed the purchase of the remaining 30% interest in the limited liability company that owns the 530 Fairview Avenue property for consideration of approximately \$2.6 million, excluding closing costs.

4. Stockholders Equity

During the nine months ended September 30, 2008, the Company issued restricted stock awards to employees and to members of its board of directors totaling 22,481 and 10,000 shares, respectively, of common stock (12,527 shares were forfeited during the same period), which are included in the total of common stock outstanding as of the period end (see Note 7). During the nine months ended September 30, 2008, the Company also issued 185,434 LTIP units to employees, which are also included in the total of common stock outstanding as of the period end (see Note 7).

On April 22, 2008, the Company completed a common stock offering of 6,129,000 shares, including the exercise of an over-allotment option of 429,000 shares, at \$25.50 per share, resulting in net proceeds of approximately \$149.6 million. The net proceeds to the Company were utilized to repay a portion of the outstanding indebtedness on the unsecured line of credit and for general corporate and working capital purposes.

Table of Contents

On October 6, 2008, the Company completed a common stock offering of 8,625,000 shares (including the exercise of the underwriter's over-allotment option with respect to 1,125,000 shares), resulting in net proceeds of approximately \$212.4 million, after deducting the underwriter's discount and commissions and estimated expenses. The net proceeds to the Company were utilized to repay a portion of the outstanding indebtedness on the unsecured line of credit and for other general corporate and working capital purposes.

In June 2007, the Company adopted a Dividend Reinvestment Program and a Cash Option Purchase Plan (collectively, the DRIP Plan) to provide existing stockholders of the Company with an opportunity to invest automatically the cash dividends paid upon shares of the Company's common stock held by them, as well as permit existing and prospective stockholders to make voluntary cash purchases. Participants may elect to reinvest a portion of, or the full amount of cash dividends paid, whereas optional cash purchases are normally limited to a maximum amount of \$10,000. In addition, the Company may elect to establish a discount ranging from 0% to 5% from the market price applicable to newly issued shares of common stock purchased directly from the Company. The Company may change the discount, initially set at 0%, at its discretion, but may not change the discount more frequently than once in any three-month period. Shares purchased under the DRIP Plan shall be, at the Company's option, purchased from either (1) authorized, but previously unissued shares of common stock, (2) shares of common stock purchased in the open market or privately negotiated transactions, or (3) a combination of both.

Common Stock, Partnership Units and LTIP Units

As of September 30, 2008, the Company had outstanding 71,720,258 shares of common stock and 2,863,564 and 640,150 partnership and LTIP units, respectively. A share of the Company's common stock and the partnership and LTIP units have essentially the same economic characteristics as they share equally in the total net income or loss and distributions of the Operating Partnership. The partnership units are further discussed in Note 3 and the LTIP units are discussed in Notes 3 and 8.

7.375% Series A Cumulative Redeemable Preferred Stock

As of September 30, 2008, the Company had outstanding 9,200,000 shares of 7.375% Series A cumulative redeemable preferred stock, or Series A preferred stock. Dividends are cumulative on the Series A preferred stock from the date of original issuance in the amount of \$1.84375 per share each year, which is equivalent to 7.375% of the \$25.00 liquidation preference per share. Dividends on the Series A preferred stock are payable quarterly in arrears on or about the 15th day of January, April, July and October of each year. Following a change in control, if the Series A preferred stock is not listed on the New York Stock Exchange, the American Stock Exchange or the Nasdaq Global Market, holders will be entitled to receive (when and as authorized by the board of directors and declared by the Company), cumulative cash dividends from, but excluding, the first date on which both the change of control and the delisting occurred at an increased rate of 8.375% per annum of the \$25.00 liquidation preference per share (equivalent to an annual rate of \$2.09375 per share) for as long as the Series A preferred stock is not listed. The Series A preferred stock does not have a stated maturity date and is not subject to any sinking fund or mandatory redemption provisions. Upon liquidation, dissolution or winding up, the Series A preferred stock will rank senior to the Company's common stock with respect to the payment of distributions and other amounts. The Company is not allowed to redeem the Series A preferred stock before January 18, 2012, except in limited circumstances to preserve its status as a REIT. On or after January 18, 2012, the Company may, at its option, redeem the Series A preferred stock, in whole or in part, at any time or from time to time, for cash at a redemption price of \$25.00 per share, plus all accrued and unpaid dividends on such Series A preferred stock up to, but excluding the redemption date. Holders of the Series A preferred stock generally have no voting rights except for limited voting rights if the Company fails to pay dividends for six or more quarterly periods (whether or not consecutive) and in certain other circumstances. The Series A preferred stock is not convertible into or exchangeable for any other property or securities of the Company.

Table of Contents**Dividends and Distributions**

The following table lists the dividends and distributions made by the Company and the Operating Partnership during the nine months ended September 30, 2008:

Declaration Date	Securities Class	Amount Per Share/Unit	Period Covered	Dividend and Distribution Payable Date	Dividend and Distribution Amount (in thousands)
March 14, 2008	Common stock and partnership and LTIP units	\$0.33500	January 1, 2008 to March 31, 2008	April 15, 2008	\$ 23,145
March 14, 2008	Series A preferred stock	\$0.46094	January 16, 2008 to April 15, 2008	April 15, 2008	\$ 4,240
June 16, 2008	Common stock and partnership and LTIP units	\$0.33500	April 1, 2008 to June 30, 2008	July 15, 2008	\$ 25,200
June 16, 2008	Series A preferred stock	\$0.46094	April 16, 2008 to July 15, 2008	July 15, 2008	\$ 4,241
September 15, 2008	Common stock and partnership and LTIP units	\$0.33500	July 1, 2008 to September 30, 2008	October 15, 2008	\$ 25,200
September 15, 2008	Series A preferred stock	\$0.46094	July 16, 2008 to October 15, 2008	October 15, 2008	\$ 4,241
Total 2008 dividends and distributions declared through September 30, 2008:					
Common stock, partnership units, and LTIP units					\$ 73,545
Series A preferred stock					12,722
					\$ 86,267

Accumulated Other Comprehensive Income

The following table provides a reconciliation of comprehensive income (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Net income	\$ 17,223	\$ 16,456	\$ 52,355	\$ 55,064
Preferred stock dividends	(4,241)	(4,241)	(12,722)	(12,628)
Net income available to common stockholders	12,982	12,215	39,633	42,436
Other comprehensive income:				
Unrealized loss on interest rate swap agreements	(7,681)	(19,606)	(9,182)	(1,472)
Equity in other comprehensive (loss)/income of unconsolidated partnerships	(202)		110	
	(1,996)		(4,823)	

Deferred settlement payments, net on interest rate
swaps (see Note 2)

Comprehensive income/(loss)	\$ 3,103	\$ (7,391)	\$ 25,738	\$ 40,964
-----------------------------	----------	------------	-----------	-----------

Table of Contents**5. Mortgage Notes Payable**

A summary of the Company's outstanding consolidated mortgage notes payable was as follows (dollars in thousands):

	Stated Fixed Interest Rate	Effective Interest Rate	Principal Balance September 30, 2008	December 31, 2007	Maturity Date
Ardentech Court	7.25%	5.06%	\$ 4,490	\$ 4,564	July 1, 2012
Bayshore Boulevard	4.55%	4.55%	15,028	15,335	January 1, 2010
Bridgeview Technology Park I	8.07%	5.04%	11,417	11,508	January 1, 2011
Eisenhower Road	5.80%	4.63%		2,113	May 5, 2008
40 Erie Street	7.34%	4.90%		17,625	August 1, 2008
500 Kendall Street (Kendall D)	6.38%	5.45%	68,226	69,437	December 1, 2018
Lucent Drive	5.50%	5.50%	5,393	5,543	January 21, 2015
Monte Villa Parkway	4.55%	4.55%	9,148	9,336	January 1, 2010
6828 Nancy Ridge Drive	7.15%	5.38%	6,718	6,785	September 1, 2012
Road to the Cure	6.70%	5.78%	15,258	15,427	January 31, 2014
Science Center Drive	7.65%	5.04%	11,189	11,301	July 1, 2011
Shady Grove Road	5.97%	5.97%	147,000	147,000	September 1, 2016
Sidney Street	7.23%	5.11%	29,390	29,986	June 1, 2012
9885 Towne Centre Drive	4.55%	4.55%	20,895	21,323	January 1, 2010
900 Uniqema Boulevard	8.61%	5.61%	1,396	1,509	May 1, 2015
			345,548	368,792	
Unamortized premiums			9,280	10,888	
			\$ 354,828	\$ 379,680	

Premiums were recorded upon assumption of the mortgage notes payable at the time of acquisition to account for above-market interest rates. Amortization of these premiums is recorded as a reduction to interest expense over the remaining term of the respective note using the effective-interest method.

The Company intends to repay any principal and accrued interest due in 2008 through the use of cash from operations or borrowings from its unsecured line of credit.

6. Credit Facilities, Exchangeable Senior Notes, and Other Debt Instruments**Unsecured Line of Credit**

The Company's unsecured line of credit with KeyBank National Association (KeyBank) and other lenders has a borrowing capacity of \$600.0 million and a maturity date of August 1, 2011. The unsecured line of credit bears interest at a floating rate equal to, at the Company's option, either (1) reserve adjusted LIBOR plus a spread which ranges from 100 to 155 basis points, depending on the Company's leverage, or (2) the higher of (a) the prime rate then in effect plus a spread which ranges from 0 to 25 basis points, or (b) the federal funds rate then in effect plus a spread which ranges from 50 to 75 basis points, in each case, depending on the Company's leverage. The Company may increase the amount of the unsecured line of credit to \$1.0 billion subject to certain conditions. In addition, the Company, at its sole discretion, may extend the maturity date of the unsecured line of credit to August 1, 2012 after satisfying certain conditions and paying an extension fee based on the then current facility commitment. As of September 30, 2008, the Company is party to two interest rate swap agreements, which were intended to have the effect of initially fixing the interest rate on interest payments associated with \$150.0 million of variable-rate debt at a weighted average rate of 5.8% through August 2011. The Company has deferred the loan costs associated with the subsequent amendments to the unsecured line of credit, which are being amortized to expense with the unamortized loan costs from the original debt facility over the remaining term. At September 30, 2008, the Company had \$266.7 million in outstanding borrowings on its unsecured line of credit, with a weighted average interest rate of 4.2% on the unhedged portion of the outstanding debt of approximately \$116.7 million.

Table of Contents***Secured Term Loan***

The Company's \$250.0 million secured term loan from KeyBank and other lenders, which is secured by the Company's interests in 12 of its properties, has a maturity date of August 1, 2012. The secured term loan bears interest at a floating rate equal to, at the Company's option, either (1) reserve adjusted LIBOR plus 165 basis points or (2) the higher of (a) the prime rate then in effect plus 25 basis points or (b) the federal funds rate then in effect plus 75 basis points. The secured term loan is also secured by the Company's interest in any distributions from these properties, a pledge of the equity interests in a subsidiary owning one of these properties, and a pledge of the equity interests in a subsidiary owning an interest in another of these properties. The Company entered into an interest rate swap agreement in connection with the initial closing of the secured term loan, which has the effect of fixing the interest rate on the secured term loan at 5.8% until the interest rate swap expires in 2010. At September 30, 2008, the Company had \$250.0 million in outstanding borrowings on its secured term loan.

The terms of the credit agreements for the unsecured line of credit and the secured term loan include certain restrictions and covenants, which limit, among other things, the payment of dividends and the incurrence of additional indebtedness and liens. The terms also require compliance with financial ratios relating to the minimum amounts of net worth, fixed charge coverage, unsecured debt service coverage, the maximum amount of secured, and secured recourse indebtedness, leverage ratio and certain investment limitations. The dividend restriction referred to above provides that, except to enable the Company to continue to qualify as a REIT for federal income tax purposes, the Company will not make distributions with respect to common stock or other equity interests in an aggregate amount for the preceding four fiscal quarters in excess of 95% of funds from operations, as defined, for such period, subject to other adjustments. Management believes that it was in compliance with the covenants as of September 30, 2008.

Exchangeable Senior Notes

On September 25, 2006, the Operating Partnership issued \$175.0 million aggregate principal amount of its 4.50% Exchangeable Senior Notes due 2026 (the "Notes"). The Notes are general senior unsecured obligations of the Operating Partnership and rank equally in right of payment with all other senior unsecured indebtedness of the Operating Partnership. Interest at a rate of 4.50% per annum is payable on April 1 and October 1 of each year, beginning on April 1, 2007, until the stated maturity date of October 1, 2026. The terms of the Notes are governed by an indenture, dated September 25, 2006, among the Operating Partnership, as issuer, the Company, as guarantor, and U.S. Bank National Association, as trustee. The Notes contain an exchange settlement feature, which provides that the Notes may, on or after September 1, 2026 or under certain other circumstances, be exchangeable for cash (up to the principal amount of the Notes) and, with respect to excess exchange value, into, at the Company's option, cash, shares of the Company's common stock or a combination of cash and shares of common stock at the then applicable exchange rate. The initial exchange rate is 26.4634 shares per \$1,000 principal amount of Notes, representing an exchange price of approximately \$37.79 per share. If certain designated events occur on or prior to October 6, 2011 and a holder elects to exchange Notes in connection with any such transaction, the Company will increase the exchange rate by a number of additional shares of common stock based on the date the transaction becomes effective and the price paid per share of common stock in the transaction, as set forth in the indenture governing the Notes. The exchange rate may also be adjusted under certain other circumstances, including the payment of cash dividends in excess of \$0.29 per share of common stock. The increase in the quarterly cash dividend to \$0.335 per share of common stock for each of the first three quarters of 2008 did not result in a material change to the exchange rate. The Operating Partnership may redeem the Notes, in whole or in part, at any time to preserve the Company's status as a REIT or at any time on or after October 6, 2011 for cash at 100% of the principal amount plus accrued and unpaid interest. The holders of the Notes have the right to require the Operating Partnership to repurchase the Notes, in whole or in part, for cash on each of October 1, 2011, October 1, 2016 and October 1, 2021, or upon the occurrence of a designated event, in each case for a repurchase price equal to 100% of the principal amount of the Notes plus accrued and unpaid interest. At September 30, 2008, the Company had an aggregate principal amount of \$175.0 million outstanding under the Notes.

Secured Construction Loan

The Company's \$550.0 million secured construction loan from KeyBank is secured by the Company's Center for Life Science | Boston property. The loan is separated into four tranches of notes, tranches A, B-1, B-2 and C, and bears interest at a blended rate equal to, at the Company's option, either (1) LIBOR plus approximately 122.5 basis

points or (2) the higher of (a) the prime rate then in effect or (b) the federal funds rate then in effect plus 50 basis points. The loan matures on November 16, 2009, but the Company may extend the maturity date to November 16, 2010 after satisfying certain conditions and payment of an extension fee. The construction loan requires interest only monthly payments until the maturity date. The Company utilized a portion of the borrowing capacity on the construction loan, along with borrowings on its unsecured line of credit, to acquire the Center for Life Science I Boston property and to fund construction activities. The loan includes certain restrictions and covenants, which limit, among other things, the incurrence of additional indebtedness and liens. The loan also requires compliance with financial covenants relating to minimum amounts of net worth, fixed charge coverage, and leverage ratio. Management believes that it was in compliance with these covenants as of September 30, 2008. At September 30, 2008, the Company had outstanding borrowings on the secured construction loan of \$501.0 million, with a weighted-average interest rate of 4.4%.

Table of Contents

As of September 30, 2008, principal payments due for the Company's consolidated indebtedness (mortgage notes payable excluding debt premium of \$9.3 million, unsecured line of credit, secured term loan, the Notes and the secured construction loan) were as follows (in thousands):

2008	\$ 1,210
2009	506,024
2010	47,446
2011	292,880
2012	291,421
Thereafter(1)	399,225
	\$ 1,538,206

(1) Includes \$175.0 million in principal payments of the Notes based on a contractual maturity date of October 1, 2026.

7. Earnings Per Share

Earnings per share is calculated based on the weighted-average number of shares of the Company's common stock outstanding during the period. The effects of the outstanding Units, and the vesting of unvested LTIP units and restricted stock that have been granted, using the treasury method, were dilutive and included in the calculation of diluted weighted-average shares for the three and nine months ended September 30, 2008 and 2007. No shares were contingently issuable upon settlement of the excess exchange value pursuant to the exchange settlement feature of the Notes (originally issued in 2006 see Note 6) as the weighted-average common stock prices of \$26.20 and \$24.17 for the three months ended September 30, 2008 and 2007, respectively, and \$24.86 and \$26.74 for the nine months ended September 30, 2008 and 2007, respectively, did not exceed the initial exchange price of \$37.79 per share. Therefore, potentially issuable shares resulting from settlement of the Notes were not included in the calculation of diluted weighted-average shares. No other shares were considered antidilutive for the three and nine months ended September 30, 2008 and 2007.

Computations of basic and diluted earnings per share in accordance with SFAS No. 128, *Earnings per Share* (in thousands, except share data) were as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Income from continuing operations and net income available for common stockholders (basic earnings per share):				
Income from continuing operations	\$ 17,223	\$ 16,457	\$ 52,355	\$ 53,412
Preferred stock dividends	(4,241)	(4,241)	(12,722)	(12,628)
Income from continuing operations available to common stockholders	12,982	12,216	39,633	40,784

(Loss)/income from discontinued operations		(1)		1,652
Net income available to common stockholders	\$ 12,982	\$ 12,215	\$ 39,633	\$ 42,436
Income from continuing operations and net income available for common stockholders (diluted earnings per share):				
Income from continuing operations available to common stockholders	\$ 12,982	\$ 12,216	\$ 39,633	\$ 40,784
Minority interests in continuing operations of operating partnership	559	545	1,767	1,821
Income from continuing operations available to common stockholders before minority interests in continuing operations	13,541	12,761	41,400	42,605
(Loss)/income from discontinued operations		(1)		1,652
Minority interest in discontinued operations of operating partnership				74
Net income available to common stockholders before minority interests	\$ 13,541	\$ 12,760	\$ 41,400	\$ 44,331
Weighted-average common shares outstanding:				
Basic	71,513,333	65,308,702	68,995,015	65,300,802
Incremental shares from assumed conversion/vesting:				
Unvested restricted stock and LTIP units using the treasury method	40,159	49,642	29,262	45,044
Operating partnership and LTIP units	3,161,349	2,916,564	3,096,052	2,916,240
Diluted	74,714,841	68,274,908	72,120,329	68,262,086
Basic and diluted earnings per share:				
<i>Income per share basic and diluted:</i>				
Income per share from continuing operations available to common stockholders	\$ 0.18	\$ 0.19	\$ 0.57	\$ 0.62
Income per share from discontinued operations				0.03
Net income per share available to common stockholders	\$ 0.18	\$ 0.19	\$ 0.57	\$ 0.65

Table of Contents**8. Incentive Award Plan**

The Company has adopted the BioMed Realty Trust, Inc. and BioMed Realty, L.P. 2004 Incentive Award Plan (the Plan). The Plan provides for grants to directors, employees and consultants of the Company and the Operating Partnership (and their respective subsidiaries) of stock options, restricted stock, LTIP units, stock appreciation rights, dividend equivalents and other incentive awards. The Company has reserved 2,500,000 shares of common stock for issuance pursuant to the Plan, subject to adjustments as set forth in the Plan. As of September 30, 2008, 1,139,842 shares of common stock or awards convertible into or exchangeable for common stock remained available for future issuance under the Plan. Each LTIP unit issued will count as one share of common stock for purposes of calculating the limit on shares that may be issued. Compensation cost for these incentive awards is measured based on the fair-value of the award on the grant date (fair-value is calculated based on the closing price of the Company's common stock on the date of grant) and is recognized as expense over the respective vesting period, which for restricted stock awards and LTIP units is generally two to five years. Fully vested incentive awards may be settled for either cash or stock depending on the Company's election and the type of award granted. Participants are entitled to cash dividends and may vote such awarded shares, but the sale or transfer of such shares is limited during the restricted or vesting period. Through September 30, 2008, the Company had only awarded restricted stock grants and LTIP units. The restricted stock grants may only be settled for stock whereas the LTIP units may be redeemed for either cash or common stock, at the Company's election.

LTIP units represent a profits interest in the Operating Partnership for services rendered or to be rendered by the LTIP unit holder in its capacity as a partner, or in anticipation of becoming a partner, in the Operating Partnership. Initially, LTIP units do not have full parity with common units of the Operating Partnership with respect to liquidating distributions, although LTIP unit holders receive the same quarterly per unit distributions as common units and may vote the LTIP units from the date of issuance. The LTIP units are subject to vesting requirements, which lapse over a specified period of time (generally three to five years from the date of issuance). In addition, the LTIP units are generally subject to a two-year lock-up period during which time the LTIP units may not be redeemed or sold by the LTIP unit holder. Upon the occurrence of specified events, LTIP units may over time achieve full parity with common units of the Operating Partnership for all purposes. Upon achieving full parity, and after the expiration of any vesting and lock-up periods, LTIP units may be redeemed for an equal number of the Company's common stock or cash, at the Company's election.

During the three months ended September 30, 2008 and 2007, the Company granted 500 shares of unvested restricted stock and LTIP units with an aggregate value of \$13,000, and 3,000 shares of unvested restricted stock and LTIP units with an aggregate value of \$78,000 under the Plan, respectively. During the nine months ended September 30, 2008 and 2007, the Company granted 217,915 shares of unvested restricted stock and LTIP units with an aggregate value of \$4.9 million, and 330,500 shares of unvested restricted stock and LTIP units with an aggregate value of \$9.8 million under the Plan, respectively. For the nine months ended September 30, 2008 and 2007, a total of 237,103 and 209,818 shares of restricted stock and LTIP units vested, with fair-values of \$5.5 million and \$6.0 million, respectively. In each of the three months ended September 30, 2008 and 2007, \$1.5 million of stock-based compensation expense was recognized in general and administrative expense and rental operations expense. For the nine months ended September 30, 2008 and 2007, \$4.3 million and \$4.1 million, respectively, of stock-based compensation expense was recognized in general and administrative expense and rental operations expense. As of September 30, 2008, total stock-based compensation expense related to unvested awards of \$12.5 million will be recognized in the future over a weighted-average period of 3.0 years.

Table of Contents

A summary of the Company's unvested restricted stock and LTIP units is presented below:

	Restricted Shares and LTIP Units	Weighted- Average Grant- Date Fair-Value
Balance at January 1, 2008	664,318	\$ 27.81
Granted	199,115	22.29
Vested	(227,103)	23.93
Balance at March 31, 2008	636,330	26.37
Granted	18,300	25.75
Forfeited	(12,327)	25.93
Vested	(10,000)	28.50
Balance at June 30, 2008	632,303	26.33
Granted	500	26.34
Forfeited	(200)	28.56
Balance at September 30, 2008	632,603	\$ 26.33

	Restricted Shares and LTIP Units	Weighted- Average Grant- Date Fair-Value
Balance at January 1, 2007	424,380	\$ 23.79
Granted	302,500	29.83
Forfeited	(3,809)	28.16
Vested	(199,818)	19.96
Balance at March 31, 2007	523,253	28.71
Granted	25,000	27.49
Forfeited	(4,450)	28.18
Vested	(10,000)	28.59
Balance at June 30, 2007	533,803	28.66
Granted	3,000	26.01
Balance at September 30, 2007	536,803	\$ 28.65

9. Property Acquisitions

The Company acquired the following property during the nine months ended September 30, 2008 (dollars in thousands):

Property	Acquisition Date	Investments	In-Place Lease	Total Cash Consideration
-----------------	-----------------------------	--------------------	---------------------------	-------------------------------------

		in Real Estate		
500 Fairview Avenue	January 28, 2008	\$ 3,286	\$727	\$ 4,013

Intangible amortization life (in months) 57

10. Investment in Unconsolidated Partnerships

The accompanying consolidated financial statements include investments in two limited liability companies with Prudential Real Estate Investors (PREI), which were formed in the second quarter of 2007, and in 10165 McKellar Court, L.P. (McKellar Court), a limited partnership with Quidel Corporation, the tenant which occupies the McKellar Court property. One of the PREI limited liability companies, PREI II LLC, is a variable interest entity as defined in FIN 46R; however, the Company is not the primary beneficiary. PREI will bear the majority of any losses. The other PREI limited liability company, PREI I LLC, does not qualify as a variable interest entity as defined in FIN 46R. In addition, consolidation under EITF 04-5 is not required as the Company does not control the limited liability companies. The McKellar Court partnership is a variable interest entity as defined in FIN 46R; however, the Company is not the primary beneficiary. The limited partner at McKellar Court is the only tenant in the property and will bear the majority of any losses. As it does not control the limited liability companies or the partnership, the Company accounts for them under the equity method of accounting. Significant accounting policies used by the unconsolidated partnerships that own these properties are similar to those used by the Company. General information on the PREI limited liability companies and the McKellar Court partnership (each referred to in this footnote individually as a partnership and collectively as the partnerships) as of September 30, 2008 was as follows:

Table of Contents

Name	Partner	Company s Ownership Interest	Company s Economic Interest	Date Acquired
PREI I LLC(1)	PREI	20%	20%	April 4, 2007
PREI II LLC(2)	PREI	20%	20%	April 4, 2007
McKellar Court(3)	Quidel Corporation	21%	21%(4)	September 30, 2004

(1) PREI I LLC acquired a portfolio of properties in Cambridge, Massachusetts comprised of a stabilized laboratory/office building totaling 184,445 square feet located at 320 Bent Street, a partially leased laboratory/office building totaling 420,000 square feet located at 301 Binney Street, a 37-unit apartment building, an operating garage facility on Rogers Street with 503 spaces, an operating below grade garage facility at Kendall Square with approximately 1,400 spaces, and a building currently under construction at 650 East Kendall Street that the Company believes can

support up to 280,000 rentable square feet of laboratory and office space. The 650 East Kendall Street site will also include a below grade parking facility that the Company estimates can support up to 560 spaces upon completion.

Each of the PREI operating agreements includes a put/call option whereby either member can cause the limited liability company to sell certain properties in which it holds leasehold interests to the Company at any time after the fifth anniversary and before the seventh anniversary of the acquisition date. However, the put/call option may be terminated prior to exercise under certain circumstances. The put/call option purchase price is based on a predetermined return on capital invested by

PREI. If the put/call option is exercised, the Company believes that it would have adequate resources to fund the purchase price and also has the option to fund a portion of the purchase price through the issuance of Company common stock.

The PREI limited liability companies jointly entered into a secured acquisition and interim loan facility with KeyBank and utilized approximately \$427.0 million of that facility to fund a portion of the purchase price for the properties acquired in April 2007. The remaining funds available are being utilized to fund construction costs at certain properties currently under development. Pursuant to the loan facility, the Company executed guaranty agreements in

which it guaranteed the full completion of the construction and any tenant improvements at the 301 Binney Street property if PREI I LLC is unable or unwilling to complete the project. The secured acquisition and interim loan facility matures on April 3, 2009.

- (2) PREI II LLC acquired a portfolio of properties comprised of a development parcel in Houston, Texas; a laboratory/office building totaling 259,706 rentable square feet and fee simple and leasehold interests in surrounding land parcels located at the Science Park at Yale in New Haven, Connecticut; and 25,000 rentable square feet of retail space and additional pad sites for future development in Cambridge, Massachusetts. On August 2,

2007, PREI II LLC completed the disposition of the 25,000 square feet of retail and additional pad sites in Cambridge, Massachusetts. The total sale price included approximately \$4.0 million contingently payable in June 2012 pursuant to a put/call option, exercisable on the earlier of the extinguishment or expiration of development restrictions placed on a portion of the development rights included in the disposition. On September 28, 2007, PREI II LLC completed the disposition of the laboratory/office building and the fee simple and leasehold interests in surrounding land parcels in New Haven, Connecticut. On December 28, 2007, PREI II LLC completed the disposition of the development parcel in

Houston, Texas. None of the sales resulted in the recognition of a material gain or loss. The Company's remaining investment in PREI II LLC (maximum exposure to losses) was approximately \$819,000 at September 30, 2008.

- (3) The McKellar Court partnership holds a property comprised of a two-story laboratory/office building totaling 72,863 rentable square feet located in San Diego, California. The Company's investment in the McKellar Court partnership (maximum exposure to losses) was approximately \$2.4 million at September 30, 2008.
- (4) The Company's economic interest in the McKellar partnership entitles it to 75% of the gains upon a sale of the property and

21% of the operating cash flows.

The Company acts as the operating member or partner, as applicable, and day-to-day manager for these partnerships. The Company is entitled to receive fees for providing construction and development services (as applicable) and management services to the PREI limited liability companies. The Company earned approximately \$612,000 and \$1.9 million in fees for the three and nine months ended September 30, 2008, respectively, and approximately \$387,000 and \$779,000 in fees for the three and nine months ended September 30, 2007 for services provided to the PREI limited liability companies, which are reflected in tenant recoveries and other income in the consolidated statements of income.

The condensed combined balance sheets for all of the Company's unconsolidated partnerships were as follows (in thousands):

	September 30, 2008	December 31, 2007
Assets:		
Investments in real estate, net	\$ 580,656	\$ 522,277
Cash and cash equivalents (including restricted cash)	5,893	8,430
Intangible assets, net	15,725	17,552
Other assets	17,487	8,488
Total assets	\$ 619,761	\$ 556,747
Liabilities and equity:		
Mortgage notes payable	\$ 499,056	\$ 426,914
Other liabilities	23,830	23,215
Members' equity	96,875	106,618
Total liabilities and equity	\$ 619,761	\$ 556,747
Company's net investment in unconsolidated partnerships	\$ 20,296	\$ 22,588

Table of Contents

On February 13, 2008, a wholly owned subsidiary of PREI I LLC entered into a secured construction loan facility with certain lenders to provide borrowings of up to approximately \$245.0 million, with a maturity date of August 13, 2010, in connection with the construction of 650 East Kendall Street, a life sciences building located in Cambridge, Massachusetts. Proceeds from the secured construction loan were used in part to repay a portion of the secured acquisition and interim loan facility held by the PREI limited liability companies and are being used to fund the balance of the anticipated cost to complete construction of the project. In February 2008, the subsidiary entered into an interest rate swap agreement, which is intended to have the effect of initially fixing the interest rate on up to \$163.0 million of the secured construction loan facility at a weighted average rate of 4.4% through August 2010. The swap agreement had an original notional amount of \$84.0 million based on the initial borrowing on the secured construction loan facility, which will increase on a monthly basis at predetermined amounts as additional borrowings are made. At September 30, 2008, there were \$127.0 million in outstanding borrowings on the secured construction loan facility, with a contractual interest rate of 4.0%.

The condensed combined statements of income for the unconsolidated partnerships were as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2008	2007	2008	2007
Total revenues	\$ 7,620	\$ 6,800	\$ 22,496	\$ 12,701
Rental operations expense	1,944	2,389	5,074	4,564
Real estate taxes	1,854	678	5,407	1,285
Depreciation and amortization	2,615	1,827	7,110	3,709
Interest expense, net of interest income	2,433	3,153	7,128	6,559
Total expenses	8,846	8,047	24,719	16,117
Net loss	\$ (1,226)	\$ (1,247)	\$ (2,223)	\$ (3,416)
Company's equity in net loss of unconsolidated partnerships	\$ (208)	\$ (261)	\$ (338)	\$ (694)

11. Discontinued Operations

During 2007, the Company sold the following property (in thousands):

Property	Date of Sale	Original Acquisition Date	Sales Price	Gain on
				Sale
Colorow Drive	May 30, 2007	December 22, 2005	\$20,000	\$ 1,087

The results of operations of the above property are reported as discontinued operations for all periods presented in the accompanying consolidated financial statements. The following is a summary of the revenue and expense components that comprise income from discontinued operations (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2008	2007	2008	2007
Total revenues	\$	\$	\$	\$ 1,111
Total expenses				472

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

Income before minority interests and gain on sale				639
(Loss)/gain on sale of real estate assets		(1)		1,087
Minority interests attributable to discontinued operations				(74)
Income from discontinued operations	\$	\$	(1)	\$ 1,652

21

Table of Contents**12. Derivatives and Other Financial Instruments**

As of September 30, 2008, the Company had four forward starting swaps hedging a forecasted debt issuance, with a total notional value of \$450.0 million, which are valued on the accompanying consolidated balance sheets at their fair-values. At maturity, the Company will either (a) receive payment from the counterparties if the accumulated balance is an asset, or (b) make payment to the counterparties if the accumulated balance is a liability with the resulting receipt or payment deferred and amortized as an increase or decrease to interest expense over the term of the forecasted borrowing.

As of September 30, 2008, the Company also had three interest rate swaps with an aggregate notional amount of \$400.0 million under which at each monthly settlement date the Company either (1) receives the difference between a fixed interest rate (the Strike Rate) and one-month LIBOR if the Strike Rate is less than LIBOR or (2) pays such difference if the Strike Rate is greater than LIBOR. One interest rate swap with a notional amount of \$250.0 million hedges the Company's secured term loan. Each of the remaining two interest rate swaps hedges the first interest payments, due on the date that is on or closest after each swap's settlement date, associated with the amount of LIBOR-based debt equal to each swap's notional amount. The two interest rate swaps have an aggregate notional amount of \$150.0 million and were initially intended to hedge interest payments associated with the Company's unsecured line of credit. No initial investment was made to enter into the interest rate swap agreements.

The following is a summary of the terms of the forward starting swaps and the interest rate swaps and their fair-values, which are included in other liabilities on the accompanying consolidated balance sheets (in thousands):

Current Notional Amount	Strike Rate	Effective Date	Expiration Date	Fair-Value(1)	
				September 30, 2008	December 31, 2007
\$ 250,000	4.157%	June 1, 2005	June 1, 2010	\$ (3,844)	\$ (2,830)
150,000	5.162%	December 30, 2008	December 30, 2018	(7,707)	(4,254)
50,000	5.167%	December 30, 2008	December 30, 2018	(2,591)	(1,437)
100,000	5.167%	December 30, 2008	December 30, 2018	(5,183)	(2,874)
150,000	5.152%	December 30, 2008	December 30, 2018	(7,673)	(4,139)
115,000	4.673%	October 1, 2007	August 1, 2011	(3,553)	(3,261)
35,000	4.700%	October 10, 2007	August 1, 2011	(1,126)	(1,019)
330,000	4.825%	September 25, 2007	September 25, 2008		(1,700)
55,000	4.760%	September 20, 2007	September 20, 2008		(254)
\$ 1,235,000				\$ (31,677)	\$ (21,768)

(1) On January 1, 2008, the Company adopted SFAS 157, which requires the

Company to disclose the framework utilized for measuring the fair-value of assets and liabilities measured at fair-value on a recurring basis (see Note 2). The Company has determined that its derivative valuations for the nine months ended September 30, 2008 in their entirety are classified in Level 2 of the fair-value hierarchy.

The increase in net unrealized losses of \$7.7 million and \$9.2 million for the three and nine months ended September 30, 2008, respectively, and decrease in net unrealized gains of (\$19.6 million) and (\$1.5 million) for the three and nine months ended September 30, 2007, respectively, for derivatives designated as cash flow hedges are separately disclosed in the accompanying footnotes to the consolidated financial statements in stockholders' equity as a component of accumulated other comprehensive income (see Note 4). For the three and nine months ended September 30, 2008, approximately \$727,000 of hedge ineffectiveness on cash flow hedges, primarily related to mismatches in the forecasted issuance date of debt related to our forward starting swaps, was recognized in interest expense. For the three and nine months ended September 30, 2007, an immaterial amount of hedge ineffectiveness on cash flow hedges due to mismatches in maturity date and interest rate reset dates of the interest rate swap and debt was recognized in interest expense.

Amounts reported in accumulated other comprehensive loss related to derivatives will be reclassified to earnings when the hedged transaction affects earnings. The change in net unrealized losses on cash flow hedges includes a reclassification of net unrealized gains/losses from accumulated other comprehensive income as an increase to interest expense of \$3.4 million and \$6.2 million for the three and nine months ended September 30, 2008, respectively, and a reduction to interest expense of \$835,000 and \$2.3 million for the three and nine months ended September 30, 2007, respectively. In addition, for the three and nine months ended September 30, 2008 approximately \$2.0 million and \$4.8 million, respectively, of settlement payments relating to our interest rate swaps have been deferred in other comprehensive income related to the Company's Center for Life Science | Boston, Pacific Research Center, and other properties currently under development or redevelopment.

Table of Contents**13. New Accounting Standards**

In December 2007, the FASB issued SFAS No. 141 (revised 2007), *Business Combinations* (SFAS 141(R)). SFAS 141(R) retains the fundamental requirements that purchase method of accounting be used for all business combinations, for an acquirer to be identified for each business combination, and retains the guidance for identifying and recognizing intangible assets separately from goodwill. SFAS 141(R) requires an acquirer to recognize the assets acquired, liabilities assumed and any noncontrolling interest in the acquiree at the acquisition date, measured at their fair-values as of that date, changes the recognition of assets acquired and liabilities assumed arising from contingencies, and changes the recognition and measurement of contingent consideration. In addition, SFAS 141(R) requires that costs incurred to effect the acquisition and restructuring costs that the acquirer expected, but is not obligated to incur, be recognized as an expense separately from the business combination. SFAS 141(R) will also require additional disclosure of information surrounding a business combination, including additional information regarding the nature and financial impact of the business combination. SFAS 141(R) applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008.

In December 2007, the FASB issued SFAS No. 160, *Noncontrolling Interests in Consolidated Financial Statements* (SFAS 160). SFAS 160 clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. SFAS 160 also requires consolidated net income to be reported at amounts that include the amounts attributable to both the parent and the noncontrolling interest and requires disclosure, on the face of the consolidated statement of income, of the amounts of consolidated net income attributable to the parent and to the noncontrolling interest. In addition, SFAS 160 establishes a single method of accounting for changes in a parent's ownership interest in a subsidiary that does not result in deconsolidation and requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated. SFAS 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. SFAS 160 may only be applied prospectively, except for the presentation and disclosure requirements, which will be applied retrospectively for all periods presented. The Company is currently evaluating the requirements of this statement and has not yet determined its effect on the Company's consolidated financial statements.

In February 2008, the FASB issued Staff Position No. FAS 157-2, which delayed the effective date of SFAS 157 for non-financial assets and liabilities to fiscal years beginning after November 15, 2008. The Company is currently evaluating the effect of the implementation of SFAS 157 on its non-financial assets and non-financial liabilities, but does not believe that it will have on a material impact on its consolidated financial statements.

In March 2008, the FASB issued SFAS No. 161, *Disclosures about Derivative Instruments and Hedging Activities* (SFAS 161) as an amendment to SFAS No. 133, *Accounting for Derivative Instruments and Hedging Activities*. SFAS 161 requires that objectives for using derivative instruments be disclosed in terms of underlying risk and accounting designation. SFAS 161 is effective for financial statements issued for fiscal years beginning after November 15, 2008. The Company is currently evaluating the requirements of this statement and its effect on the Company's consolidated financial statements.

In May 2008, the FASB issued FASB Staff Position APB 14-1, *Accounting for Convertible Debt Instruments That May Be Settled in Cash Upon Conversion (Including Partial Cash Settlement)* (FSP 14-1), an interpretation of APB Opinion No. 14, *Accounting for Convertible Debt and Debt Issued with Stock Purchase Warrants*. FSP 14-1 requires the issuer of certain convertible debt instruments that may be settled in cash (or other assets) on conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer's nonconvertible debt borrowing rate. The equity component of the convertible debt will be included in the paid-in capital section of stockholders' equity and the value of the equity component will be treated as original issue discount for purposes of accounting for the debt component of the debt security. The resulting debt discount will be accreted as additional interest expense over the non-cancellable term of the instrument. FSP 14-1 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2008, with early adoption not permitted. Retrospective application is required for all periods presented. The Company believes FSP 14-1 will result in an increase to interest expense associated with the Notes and also will result in an increase in

capitalized interest upon adoption.

In June 2008, the FASB issued FASB Staff Position EITF 03-6-1, *Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities* (FSP 03-6-1), which addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting and, therefore, need to be included in earnings allocation in computing earnings per share under the two-class method. The statement is effective for financial statements issued for fiscal years beginning after December 15, 2008 and retrospective application is required for all periods presented. The Company is currently evaluating the effect of the implementation of FSP 03-6-1, but does not believe that it will have a material impact on the calculation of earnings per share.

Table of Contents**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

As used herein, the terms we, us, our or the Company refer to BioMed Realty Trust, Inc., a Maryland corporation and any of our subsidiaries.

The following discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere in this report. We make statements in this report that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, statements pertaining to our capital resources, portfolio performance and results of operations contain forward-looking statements. Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise, and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). You can identify forward-looking statements by the use of forward-looking terminology such as believes, expects, may, will, should, seeks, approximately, intends, estimates or anticipates or the negative of these words and phrases or similar words or phrases. You can also identify forward-looking statements by discussions of strategy, plans or intentions. The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or our target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively our growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the financial and securities markets; potential liability for uninsured losses and environmental contamination; risks associated with our potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, or the Code, and possible adverse changes in tax and environmental laws; and risks associated with our dependence on key personnel whose continued service is not guaranteed. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The risks included here are not exhaustive, and additional factors could adversely affect our business and financial performance, including factors and risks included in other sections of this report. In addition, we discussed a number of material risks in our annual report on Form 10-K for the year ended December 31, 2007. Those risks continue to be relevant to our performance and financial condition. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on our company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Overview

We operate as a REIT focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry. Our tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. Our properties are generally located in markets with well-established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey.

At September 30, 2008, our portfolio consisted of 69 properties, representing 112 buildings with an aggregate of approximately 10.4 million rentable square feet, including 1.4 million square feet of development in progress. We also owned undeveloped land parcels adjacent to existing properties that we estimate can support up to 1.4 million rentable square feet of laboratory and office space.

Table of Contents

The following reflects the classification of our properties between stabilized properties (operating properties in which more than 90% of the rentable square footage is under lease), lease up properties (operating properties in which less than 90% of the rentable square footage is under lease), repositioning and redevelopment properties (properties that are currently being prepared for their intended use), construction in progress (properties that are currently under development through ground up construction), and land parcels (representing management's estimates of rentable square footage if development of these properties was undertaken) at September 30, 2008:

	Consolidated Portfolio			Unconsolidated Partnership Portfolio			Total Portfolio		
	Properties	Rentable Square Feet	Percent of Rentable Square Feet Leased	Properties	Rentable Square Feet	Percent of Rentable Square Feet Leased	Properties	Rentable Square Feet	Percent of Rentable Square Feet Leased
Stabilized properties	43	5,340,037	99.4%	4	257,308	100.0%	47	5,597,345	99.5%
Lease up properties	13	1,287,626	63.6%	2	420,000	26.8%	15	1,707,626	54.6%
Total operating portfolio	56	6,627,663	92.5%	6	677,308	54.6%	62	7,304,971	89.0%
Repositioning and redevelopment properties	3	1,676,651	20.1%			n/a	3	1,676,651	20.1%
Construction in progress	3	1,157,000	70.0%	1	280,000	n/a	4	1,437,000	56.4%
Total portfolio	62	9,461,314	76.9%	7	957,308	38.6%	69	10,418,622	73.4%
Land parcels	n/a	1,367,000	n/a			n/a		1,367,000	n/a
Total proforma portfolio(1)	62	10,828,314	n/a	7	957,308	n/a	69	11,785,622	n/a

(1) Percent of rentable square feet leased excludes undeveloped land parcels.

Factors Which May Influence Future Operations

Our corporate strategy is to continue to focus on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry. Approximately 0.7% of our leased square footage expires during the remainder of 2008 and approximately 3.3% of our leased square footage expires during 2009. Our leasing strategy focuses on leasing currently vacant space, negotiating renewals for expiring leases and identifying new tenants or existing tenants seeking additional space to occupy the spaces for which we are unable to negotiate such renewals.

The success of our leasing and development strategy will depend upon the general economic conditions in the United States and in our target markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania, New York/New Jersey and research parks near or adjacent to universities.

A more complete discussion of the factors which may influence future operations can be found in our annual report on Form 10-K for the year ended December 31, 2007.

Critical Accounting Policies

A complete discussion of our critical accounting policies can be found in our annual report on Form 10-K for the year ended December 31, 2007.

New Accounting Standards

See Notes to Consolidated Financial Statements (Unaudited) included elsewhere herein for disclosure of new accounting standards.

Table of Contents**Results of Operations****Comparison of the Three Months Ended September 30, 2008 to the Three Months Ended September 30, 2007**

The following table sets forth the basis for presenting the historical financial information for same properties (all properties except redevelopment/development and new properties and discontinued operations), redevelopment/development properties (properties that were entirely or primarily under redevelopment or development during either of the three months ended September 30, 2008 or 2007), new properties (properties that were not owned for each of the three months ended September 30, 2008 and 2007 and were not under redevelopment/development), and corporate entities (legal entities performing general and administrative functions and fees received from our PREI joint venture limited liability companies), in thousands:

	Redevelopment/Development							
	Same Properties		Properties		New Properties		Corporate	
	2008	2007	2008	2007	2008	2007	2008	2007
Rental	\$ 48,836	\$ 47,204	\$ 9,410	\$ 1,827	\$ 1,139	\$ 356	\$ (4)	\$ (5)
Tenant recoveries	15,701	14,412	4,802	618	233	57	175	(3)
Other income	71	(7)					448	373
Total revenues	\$ 64,608	\$ 61,609	\$ 14,212	\$ 2,445	\$ 1,372	\$ 413	\$ 619	\$ 365

Rental Revenues. Rental revenues increased \$10.0 million to \$59.4 million for the three months ended September 30, 2008 compared to \$49.4 million for the three months ended September 30, 2007. The increase was primarily due to acquisitions during 2007 and 2008 and properties that were under redevelopment or development in the prior year for which partial revenue recognition commenced during 2008 (principally at our Center for Life Science | Boston, 217th Place, and 9865 Towne Centre Drive properties), partially offset by lease expirations and properties for which rental revenues were recognized in 2007, but were subsequently placed under redevelopment. In addition, same property rental revenues increased \$1.6 million, or 3.5%, for the three months ended September 30, 2008 compared to the same period in 2007. The increase in same property rental revenues was primarily a result of the expansion of an existing lease at our King of Prussia property, new leases at our Landmark at Eastview, Road to the Cure and Phoenixville Pike properties, and a CPI rental adjustment at one property.

Tenant Recoveries. Revenues from tenant reimbursements increased \$5.8 million to \$20.9 million for the three months ended September 30, 2008 compared to \$15.1 million for the three months ended September 30, 2007. The increase was primarily due to properties that were under redevelopment or development in the prior year for which tenant recoveries commenced during 2008 (principally at our Center for Life Science | Boston property), partially offset by properties for which tenant recoveries were recognized in 2007, but which were subsequently placed under redevelopment. In addition, same property tenant recoveries increased \$1.3 million, or 9.0%, for the three months ended September 30, 2008 compared to the same period in 2007 primarily as a result of net increases in utility usage and other recoverable costs compared to the prior year, partially offset by a change in 2008 at one property in which the tenant began to directly pay a vendor for certain recoverable expenses.

Other Income. Other income was \$519,000 for the three months ended September 30, 2008 compared to \$366,000 for the three months ended September 30, 2007. Other income for the three months ended September 30, 2008 and 2007 was primarily comprised of fees earned from our PREI joint venture limited liability companies.

The following tables show operating expenses for same properties, redevelopment/development properties, new properties, and corporate entities, in thousands:

	Redevelopment/Development							
	Same Properties		Properties		New Properties		Corporate	
	2008	2007	2008	2007	2008	2007	2008	2007
Rental operations	\$ 11,842	\$ 11,554	\$ 4,160	\$ 491	\$ 420	\$ 25	\$ 605	\$ 719
Real estate taxes	5,103	4,792	1,560	239	119	48	(19)	

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

Depreciation and amortization	16,761	16,508	4,149	1,021	596	136		
Total expenses	\$ 33,706	\$ 32,854	\$ 9,869	\$ 1,751	\$ 1,135	\$ 209	\$ 586	\$ 719

Rental Operations Expense. Rental operations expense increased \$4.2 million to \$17.0 million for the three months ended September 30, 2008 compared to \$12.8 million for the three months ended September 30, 2007. The increase was partly due to the inclusion of rental operations expense for properties acquired during 2007 and 2008 and properties that were under redevelopment or development in the prior year for which operations commenced during 2008 (principally at our Center for Life Science I Boston property), as well as an increase in same property rental operations expense of \$288,000, or 2.5%, for the three months ended September 30, 2008 compared to the same period in 2007. The increase in same property rental operations expense was primarily due to net increases in utility usage and other costs compared to the prior year, and higher reimbursable repairs and maintenance costs at certain properties compared to the same period in the prior year, partially offset by a change in 2008 at one property in which the tenant began to directly pay a vendor for certain recoverable expenses.

Table of Contents

Real Estate Tax Expense. Real estate tax expense increased \$1.7 million to \$6.8 million for the three months ended September 30, 2008 compared to \$5.1 million for the three months ended September 30, 2007. The increase was primarily due to properties that were under redevelopment or development in the prior year for which operations commenced during 2008 (principally at our Center for Life Science | Boston property). Same property real estate tax expense increased \$311,000, or 6.5%, for the three months ended September 30, 2008 compared to the same period in the prior year, primarily due to real estate tax refunds in the same period in 2007.

Depreciation and Amortization Expense. Depreciation and amortization expense increased \$3.8 million to \$21.5 million for the three months ended September 30, 2008 compared to \$17.7 million for the three months ended September 30, 2007. The increase was primarily due to properties that were under redevelopment or development in the prior year for which operations commenced during 2008 (principally at our Center for Life Science | Boston property), partially offset by lease expirations and properties for which depreciation and amortization expense was recognized in 2007, but were subsequently placed under redevelopment.

General and Administrative Expenses. General and administrative expenses decreased \$694,000 to \$4.6 million for the three months ended September 30, 2008 compared to \$5.3 million for the three months ended September 30, 2007. The decrease was primarily due to a reduction of the estimated bonus compensation for senior management, partially offset by higher expenses associated with continued growth in the corporate infrastructure necessary to support our expanded property portfolio.

Equity in Net Loss of Unconsolidated Partnerships. Equity in net loss of unconsolidated partnerships decreased \$53,000 to a net loss of \$208,000 for the three months ended September 30, 2008 compared to a net loss of \$261,000 for the three months ended September 30, 2007. The decrease was primarily due to the sale of certain properties owned by our PREI joint venture limited liability companies during September 2007 which recognized operating losses in 2007 and the commencement of leases at certain properties of our PREI joint venture limited liability companies during 2008, partially offset by the cessation of the capitalization of interest and operating expenses at those properties.

Interest Expense. Interest cost incurred for the three months ended September 30, 2008 decreased to \$21.5 million compared to \$21.9 million for the three months ended September 30, 2007, primarily due to a decrease in interest rates compared to the same period in the prior year, partially offset by an increase in borrowing related to development and redevelopment activities. During the three months ended September 30, 2008, we capitalized \$8.4 million of interest compared to \$14.9 million for the three months ended September 30, 2007. The decrease in capitalized interest reflects the partial or complete cessation of capitalized interest at our Center for Life Science | Boston, 9865 Towne Centre Drive, and 500 Fairview Avenue development projects and our Pacific Research Center redevelopment project due to the commencement of certain leases at those properties. We expect capitalized interest costs on these and other properties currently under development or redevelopment to decrease as leased spaces at these properties are readied for their intended uses throughout the remainder of 2008. Net of capitalized interest and the accretion of debt premium, interest expense was \$13.0 million and \$7.0 million for the three months ended September 30, 2008 and 2007, respectively.

Minority Interests. Minority interests increased \$76,000 to \$570,000 for the three months ended September 30, 2008 compared to \$494,000 for the three months ended September 30, 2007. The increase in minority interests was primarily related to an increase in income at our consolidated joint ventures allocable to minority interests.

Comparison of the Nine Months Ended September 30, 2008 to the Nine Months Ended September 30, 2007

The following table sets forth the basis for presenting the historical financial information for same properties (all properties except redevelopment/development and new properties and discontinued operations), redevelopment/development properties (properties that were entirely or primarily under redevelopment or development during either of the nine months ended September 30, 2008 or 2007), new properties (properties that were not owned for each of the nine months ended September 30, 2008 and 2007 and were not under redevelopment/development), and corporate entities (legal entities performing general and administrative functions and fees received from our PREI joint venture limited liability companies), in thousands:

Redevelopment/Development

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

	Same Properties		Properties		New Properties		Corporate	
	2008	2007	2008	2007	2008	2007	2008	2007
Rental	\$ 135,464	\$ 132,370	\$ 16,881	\$ 9,129	\$ 11,614	\$ 4,862	\$ (13)	\$ (10)
Tenant recoveries	44,871	41,658	6,669	5,099	1,315	510	442	(3)
Other income	228	488	2	7,171			1,467	786
Total revenues	\$ 180,563	\$ 174,516	\$ 23,552	\$ 21,399	\$ 12,929	\$ 5,372	\$ 1,896	\$ 773

27

Table of Contents

Rental Revenues. Rental revenues increased \$17.5 million to \$163.9 million for the nine months ended September 30, 2008 compared to \$146.4 million for the nine months ended September 30, 2007. The increase was primarily due to acquisitions during 2007 and 2008 and properties that were under redevelopment or development in the prior year for which partial revenue recognition commenced during 2008 (principally at our Center for Life Science | Boston property), partially offset by properties that generated rental revenues in 2007, which were subsequently placed under redevelopment. In addition, same property rental revenues increased \$3.1 million, or 2.3%, for the nine months ended September 30, 2008 compared to the same period in 2007. The increase in same property rental revenues was primarily a result of the expansion of an existing lease at our King of Prussia property, new leases at our Landmark at Eastview, Road to the Cure and Phoenixville Pike properties, and a CPI rental adjustment at one property, partially offset by the expiration of a lease at our Ardenwood Venture property in 2007.

Tenant Recoveries. Revenues from tenant reimbursements increased \$6.0 million to \$53.3 million for the nine months ended September 30, 2008 compared to \$47.3 million for the nine months ended September 30, 2007. The increase was primarily due to the commencement of new leases at a number of properties, increases in utility usage and rates, acquisitions during 2007 and 2008, and an increase in fees earned from our PREI joint venture limited liability companies. Same property tenant recoveries increased \$3.2 million, or 7.7%, for the nine months ended September 30, 2008 compared to the same period in 2007 primarily as a result of net increases in utility usage and other recoverable costs compared to the prior year, partially offset by a change in 2008 at one property in which the tenant began to directly pay a vendor for certain recoverable expenses.

Other Income. Other income was \$1.7 million for the nine months ended September 30, 2008 compared to \$8.4 million for the nine months ended September 30, 2007. Other income for the nine months ended September 30, 2007 was primarily comprised of gains on early termination of leases and fees earned from our PREI joint venture limited liability companies. Other income for the nine months ended September 30, 2008 was primarily comprised of fees earned from our PREI joint venture limited liability companies.

The following tables show operating expenses for same properties, redevelopment/development properties, new properties, and corporate entities, in thousands:

	Redevelopment/Development							
	Same Properties		Properties		New Properties		Corporate	
	2008	2007	2008	2007	2008	2007	2008	2007
Rental operations	\$ 34,884	\$ 33,539	\$ 5,897	\$ 3,319	\$ 1,369	\$ 192	\$ 2,195	\$ 1,734
Real estate taxes	13,775	14,060	2,350	2,076	840	402	(17)	
Depreciation and amortization	46,579	46,006	7,718	6,859	4,228	1,691		
Total expenses	\$ 95,238	\$ 93,605	\$ 15,965	\$ 12,254	\$ 6,437	\$ 2,285	\$ 2,178	\$ 1,734

Rental Operations Expense. Rental operations expense increased \$5.5 million to \$44.3 million for the nine months ended September 30, 2008 compared to \$38.8 million for the nine months ended September 30, 2007. The increase was primarily due to acquisitions during 2007 and 2008 and properties that were under redevelopment or development in the prior year for which partial revenue recognition commenced during 2008 (principally at our Center for Life Science | Boston property), partially offset by properties that generated rental revenues in 2007, which were subsequently placed under redevelopment. Same property rental operations expense increased \$1.3 million, or 4.0%, for the nine months ended September 30, 2008 compared to the same period in 2007 primarily due to the hiring of additional property management personnel and related expansion of our operations in 2007 and 2008, net increases in utility usage and other recoverable costs, and higher reimbursable repairs and maintenance costs at certain properties compared to the same period in the prior year, partially offset by a change in 2008 at one property in which the tenant began to directly pay a vendor for certain recoverable expenses.

Real Estate Tax Expense. Real estate tax expense increased \$410,000 to \$16.9 million for the nine months ended September 30, 2008 compared to \$16.5 million for the nine months ended September 30, 2007. The increase was

primarily due to acquisitions during 2007 and 2008 and properties that were under redevelopment or development in the prior year for which partial revenue recognition commenced during 2008 (principally at our Center for Life Science | Boston property), partially offset by a decrease in same property real estate tax expense of \$285,000, or 2.0%, for the nine months ended September 30, 2008 compared to the same period in the prior year. The decrease in same property real estate tax expense is primarily due to a decrease in tax rates, tax refunds, and the capitalization of property taxes in connection with construction on the undeveloped portion of our Landmark at Eastview property.

Depreciation and Amortization Expense. Depreciation and amortization expense increased \$3.9 million to \$58.5 million for the nine months ended September 30, 2008 compared to \$54.6 million for the nine months ended September 30, 2007. The increase was primarily due to depreciation and amortization expense for the properties acquired in 2007 and 2008 and the commencement of partial operations and recognition of depreciation and amortization expense at certain of our redevelopment and development properties, partially offset by the cessation of depreciation on certain properties, or portions thereof, which were placed under redevelopment in 2007 and 2008.

Table of Contents

General and Administrative Expenses. General and administrative expenses increased \$438,000 to \$16.4 million for the nine months ended September 30, 2008 compared to \$16.0 million for the nine months ended September 30, 2007. The increase was primarily due to continued growth in the corporate infrastructure necessary to support our expanded property portfolio, an increase in stock-based compensation costs, costs associated with improvements at our new corporate headquarters, which was completed in the first quarter of 2008, and costs related to our headquarters relocation, partially offset by a reduction of the estimated bonus compensation for senior management.

Equity in Net Loss of Unconsolidated Partnerships. Equity in net loss of unconsolidated partnerships decreased \$356,000 to a net loss of \$338,000 for the nine months ended September 30, 2008 compared to a net loss of \$694,000 for the nine months ended September 30, 2007. The decrease was primarily due to the commencement of leases at certain properties of our PREI joint venture limited liability companies in 2008, partially offset by the cessation of the capitalization of interest and operating expenses at those properties.

Interest Expense. Interest cost incurred for the nine months ended September 30, 2008 increased to \$63.2 million compared to \$61.7 million for the nine months ended September 30, 2007, primarily due to an increase in borrowing related to development and redevelopment activities, partially offset by a decrease in interest rates compared to the same period in the prior year. During the nine months ended September 30, 2008, we capitalized \$34.6 million of interest compared to \$40.6 million for the nine months ended September 30, 2007. The decrease in capitalized interest reflects the partial or complete cessation of capitalized interest at our Center for Life Science | Boston, 9865 Towne Centre Drive, and 500 Fairview Avenue development projects and our Pacific Research Center redevelopment project due to the commencement of certain leases at those properties. We expect capitalized interest costs on these and other properties currently under development or redevelopment to decrease as leased spaces at these properties are readied for their intended uses throughout the remainder of 2008. Net of capitalized interest and the accretion of debt premium, interest expense was \$28.6 million and \$21.0 million for the nine months ended September 30, 2008 and 2007, respectively.

Minority Interests. Minority interests decreased \$111,000 to \$1.8 million for the nine months ended September 30, 2008 compared to \$1.9 million for the nine months ended September 30, 2007. The decrease in minority interests was primarily related to a decrease in income at our consolidated joint ventures allocable to minority interests and at our operating partnership allocable to minority interests.

Discontinued Operations. In May 2007, we completed the sale of our Colorow property and recognized a gain upon closing of approximately \$1.1 million. The results of operations and gain on sale of the property have been reported as discontinued operations in the consolidated statements of income for the nine months ended September 30, 2008. Income from discontinued operations for the nine months ended September 30, 2008 was comprised of income generated by the property and the gain on sale.

Cash Flows***Comparison of the Nine Months Ended September 30, 2008 to the Nine Months Ended September 30, 2007***

	2008	2007 (In thousands)	Change
Net cash provided by operating activities	\$ 81,816	\$ 83,155	\$ (1,339)
Net cash used in investing activities	(182,374)	(325,824)	143,450
Net cash provided by financing activities	110,530	235,429	(124,899)
Ending cash and cash equivalents balance	23,451	18,424	5,027

Net cash provided by operating activities decreased \$1.3 million to \$81.8 million for the nine months ended September 30, 2008 compared to \$83.1 million for the nine months ended September 30, 2007. The decrease was primarily due to changes in operating assets and liabilities, partially offset by an increase in income before depreciation and amortization.

Net cash used in investing activities decreased \$143.4 million to \$182.4 million for the nine months ended September 30, 2008 compared to \$325.8 million for the nine months ended September 30, 2007. The decrease was primarily due to fewer property acquisitions, including those acquired through investments in unconsolidated partnerships, partially offset by the investment in non-real estate assets (primarily related to our relocation to a new

corporate headquarters) and the absence of property dispositions in 2008.

Net cash provided by financing activities decreased \$124.9 million to \$110.5 million for the nine months ended September 30, 2008 compared to \$235.4 million for the nine months ended September 30, 2007. The decrease was primarily due to lower proceeds from equity offerings as compared to the prior year, lower unsecured line of credit and construction loan borrowings, and higher payments of dividends and distributions.

Table of Contents**Funds from Operations**

We present funds from operations, or FFO, available to common shares and partnership and LTIP units because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. FFO is intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO excludes depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, it provides a performance measure that, when compared year over year, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT, in its March 1995 White Paper (as amended in November 1999 and April 2002). As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures. Our computation may differ from the methodology for calculating FFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO does not represent amounts available for management's discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO should not be considered as an alternative to net income (loss) (computed in accordance with GAAP) as an indicator of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to pay dividends or make distributions.

Our FFO available to common shares and partnership and LTIP units and a reconciliation to net income (in thousands, except share data) was as follows:

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2008	2007	2008	2007
Net income available to common stockholders	\$ 12,982	\$ 12,215	\$ 39,633	\$ 42,436
Adjustments:				
Minority interests in operating partnership	559	545	1,767	1,895
Loss/(gain) on sale of real estate assets		1		(1,087)
Depreciation and amortization unconsolidated partnerships	524	366	1,425	745
Depreciation and amortization consolidated entities-discontinued operations				228
Depreciation and amortization consolidated entities-continuing operations	21,506	17,665	58,525	54,556
Depreciation and amortization allocable to minority interest of consolidated joint ventures	(8)		(25)	
Funds from operations available to common shares and partnership and LTIP units	\$ 35,563	\$ 30,792	\$ 101,325	\$ 98,773
Funds from operations per share diluted	\$ 0.48	\$ 0.45	\$ 1.40	\$ 1.45
Weighted-average common shares outstanding diluted	74,714,841	68,274,908	72,120,329	68,262,086

Liquidity and Capital Resources

Our short-term liquidity requirements consist primarily of funds to pay for future distributions expected to be paid to our stockholders, operating expenses and other expenditures directly associated with our properties, interest expense and scheduled principal payments on outstanding indebtedness, general and administrative expenses, and capital expenditures, tenant improvements and leasing commissions.

We expect to satisfy our short-term liquidity requirements through our existing working capital and cash provided by our operations. Our rental revenues, provided by our leases, generally provide cash inflows to meet our debt service obligations, pay general and administrative expenses, and fund regular distributions.

Table of Contents

Our long-term liquidity requirements consist primarily of funds to pay for scheduled debt maturities, swap settlements, construction obligations, renovations, expansions, capital commitments and other non-recurring capital expenditures that need to be made periodically, and the costs associated with acquisitions of properties that we pursue. Debt maturities through 2009 include our secured construction loan and our secured acquisition and interim loan facility (held by our PREI limited liability companies in which we own a 20% interest) with outstanding balances of \$501.0 million and \$361.7 million, respectively, as of September 30, 2008. The secured construction loan matures in November 2009, but we may extend the maturity date for one year through November 16, 2010 after satisfying certain conditions and payment of an extension fee. The secured acquisition and interim loan facility matures in April 2009. We also have four forward starting swaps that will require cash settlement on or before April 30, 2009. Based upon the fair-value of the forward starting swaps as of September 30, 2008, such cash settlement would require us to pay the counterparties approximately \$23.2 million; however, the actual cash settlement amount will depend on the values of the forward starting swaps at the date they are settled and the actual cash settlement amount may be significantly more or less than \$23.2 million. See Note 12 to the unaudited consolidated financial statements for a discussion of the accounting for the forward starting swaps.

We expect to satisfy these and other long-term liquidity requirements through our existing working capital, cash provided by operations, long-term secured and unsecured indebtedness, the issuance of additional equity or debt securities and the use of net proceeds from the disposition of non-strategic assets. We also expect to use funds available under our unsecured line of credit to finance acquisition and development activities and capital expenditures on an interim basis. Continued uncertainty in the credit markets may negatively impact our ability to access additional debt financing or to refinance existing debt maturities on favorable terms (or at all), which may negatively affect our ability to make acquisitions and fund current and future development and redevelopment projects. In addition, the financial positions of the lenders under our credit facilities may worsen to the point that they default on their obligations to make available to us the funds under those facilities. A prolonged downturn in the credit markets may cause us to seek alternative sources of potentially less attractive financing, and may require us to adjust our business plans accordingly.

Under the rules adopted by the Securities and Exchange Commission regarding registration and offering procedures, if we meet the definition of a well-known seasoned issuer under Rule 405 of the Securities Act of 1933, as amended, or Securities Act, we are permitted to file an automatic shelf registration statement that will be immediately effective upon filing. On September 15, 2006, we filed such an automatic shelf registration statement, which may permit us, from time to time, to offer and sell debt securities, common stock, preferred stock, warrants and other securities to the extent necessary or advisable to meet our liquidity needs.

On April 22, 2008, we completed a common stock offering of 6,129,000 shares (including the exercise of the underwriters' over-allotment option with respect to 429,000 shares) at \$25.50 per share, resulting in net proceeds of approximately \$149.6 million. The net proceeds were utilized to repay a portion of the outstanding indebtedness on the unsecured line of credit and for general corporate and working capital purposes.

On October 6, 2008, we completed a common stock offering of 8,625,000 shares (including the exercise of the underwriter's over-allotment option with respect to 1,125,000 shares), resulting in net proceeds of approximately \$212.4 million, after deducting the underwriter's discount and commissions and estimated expenses. The net proceeds to us were utilized to repay a portion of the outstanding indebtedness on the unsecured line of credit and for other general corporate and working capital purposes.

Our total capitalization at September 30, 2008 was approximately \$3.8 billion and was comprised of the following:

Shares/Units at September 30, 2008	Aggregate Principal Amount or Dollar Value Equivalent	Percent of Total Capitalization
---	--	--

(In thousands)			
Debt:			
Mortgage notes payable (1)		\$ 354,828	9.4%
Secured construction loan		500,998	13.3%
Secured term loan		250,000	6.6%
Exchangeable senior notes		175,000	4.6%
Unsecured line of credit		266,660	7.1%
Total debt		1,547,486	41.0%
Equity:			
Common shares outstanding (2)	71,720,258	1,897,001	50.5%
7.375% Series A Preferred shares outstanding (3)	9,200,000	230,000	6.1%
Operating partnership units outstanding (4)	2,863,564	75,741	2.0%
LTIP units outstanding (4)	640,150	16,932	0.4%
Total equity		2,219,674	59.0%
Total capitalization		\$ 3,767,160	100.0%

(1) Amount includes debt premiums of \$9.3 million recorded upon the assumption of the outstanding indebtedness in connection with our purchase of the corresponding properties.

(2) Based on the market closing price of our common stock of \$26.45 per share on the last trading day of the quarter (September 30, 2008).

(3) Based on the liquidation preference of \$25.00 per share for our 7.375%

Series A
preferred stock.

- (4) Based on common stock equivalents of our partnership and LTIP units, which are each individually convertible into one share of common stock using the market closing price of our common stock of \$26.45 per share on the last trading day of the quarter (September 30, 2008).

Table of Contents

As a result, our debt to total capitalization ratio was approximately 41.0% at September 30, 2008 (excluding our proportionate share of indebtedness from our unconsolidated partnerships). As noted, on October 6, 2008 we completed a common stock offering, the net proceeds of which were used to repay a portion of our outstanding indebtedness. In addition, subsequent to September 30, 2008 the per share price of our common stock declined significantly. On a pro forma basis, considering the effects of the offering, use of net proceeds and subsequent borrowings and the decline in the per share price of our stock, as of October 28, 2008 our debt to total capitalization ratio was approximately 47.3%.

Our board of directors adopted a policy of limiting our indebtedness to approximately 60% of our total capitalization. However, our board of directors may from time to time modify our debt policy in light of economic or market conditions including, but not limited to, the relative costs of debt and equity capital, market conditions for debt and equity securities and fluctuations in the market price of our common stock. Accordingly, we may increase or decrease our debt to total capitalization ratio beyond the limit described above.

We may from time to time seek to repurchase or redeem our outstanding debt, shares of common stock or preferred stock or other securities in open market purchases, privately negotiated transactions or otherwise. Such repurchases or redemptions, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors.

Off Balance Sheet Arrangements

As of September 30, 2008, we had investments in the following unconsolidated partnerships: (1) McKellar Court limited partnership, which owns a single tenant occupied property located in San Diego; and (2) two limited liability companies with PREI, which own a portfolio of properties primarily located in Boston (see Note 10).

McKellar Court is a variable interest entity as defined in FIN 46R; however, we are not the primary beneficiary. The limited partner at McKellar Court is the only tenant in the property and will bear a disproportionate amount of any losses. We, as the general partner, will receive 21% of the operating cash flows and 75% of the gains upon sale of the property. We account for our general partner interest using the equity method. The assets of McKellar Court were \$16.3 million and \$16.6 million and the liabilities were \$10.7 million and \$10.8 million at September 30, 2008 and December 31, 2007, respectively. Our equity in net income of McKellar Court was \$22,000 and \$22,000 for the three months ended September 30, 2008 and 2007, respectively, and \$63,000 and \$64,000 for the nine months ended September 30, 2008 and 2007, respectively.

PREI II LLC is a variable interest entity as defined in FIN 46R; however, we are not the primary beneficiary. PREI will bear the majority of any losses incurred. PREI I LLC does not qualify as a variable interest entity as defined in FIN 46R. In addition, consolidation under EITF 04-5 is not required as we do not control the limited liability companies. In connection with the formation of the PREI limited liability companies in April 2007, we contributed 20% of the initial capital. However, the amount of cash flow distributions that we may receive may be more or less based on the nature of the circumstances underlying the cash distributions due to provisions in the operating agreements governing the distribution of funds to each member and the occurrence of extraordinary cash flow events. We account for our member interests using the equity method for both limited liability companies. The assets of the PREI limited liability companies were \$603.4 million and \$540.3 million and the liabilities were \$512.2 million and \$439.4 million at September 30, 2008 and December 31, 2007, respectively. Our equity in net loss of the PREI limited liability companies (net of intercompany eliminations) were losses of \$229,000 and \$293,000 for the three months ended September 30, 2008 and 2007, respectively, and losses of \$399,000 and \$767,000 for the nine months ended September 30, 2008 and 2007, respectively.

We have been the primary beneficiary in four other variable interest entities, which are consolidated and reflected in our consolidated financial statements.

Our proportionate share of outstanding debt related to our unconsolidated partnerships is summarized below (dollars in thousands):

Name	Ownership Percentage	Principal Amount (1)
-------------	---------------------------------	-----------------------------

		Interest Rate (2)	September 30, 2008	December 31, 2007	Maturity Date
PREI I and PREI II(3)	20%	3.44%	\$ 72,338	\$ 83,285	April 3, 2009
PREI I(4)	20%	4.35%	25,395		August 13, 2010
McKellar Court(5)	21%	4.63%	2,182	2,203	January 1, 2010
Total			\$ 99,915	\$ 85,488	

(1) Amount represents our proportionate share of the total outstanding indebtedness for each of the unconsolidated partnerships.

(2) Effective or weighted average interest rate of the outstanding indebtedness as of September 30, 2008.

(3) Amount represents our proportionate share of the total draws outstanding under a secured acquisition and interim loan facility, which bears interest at a LIBOR-indexed variable-rate. The secured acquisition and interim loan facility was utilized by both

PREI I LLC and PREI II LLC to acquire a portfolio of properties (initial borrowings of approximately \$427.0 million) on April 4, 2007 (see Note 10 in the accompanying consolidated financial statements). The remaining balance is being utilized to fund construction costs at certain properties currently under development. On February 19, 2008, the maturity date was extended to April 3, 2009.

- (4) Amount represents our proportionate share of a secured construction loan, which bears interest at a LIBOR-indexed variable-rate. The secured construction loan was executed by a wholly owned subsidiary of PREI I LLC in connection with the construction of the 650 East

Kendall Street property (initial borrowings of \$84.0 million on February 13, 2008 were used in part to repay a portion of the secured acquisition and interim loan facility). The remaining balance is being utilized to fund construction costs at the property.

- (5) Amount represents our proportionate share of the principal balance outstanding on a mortgage note payable, which is secured by the McKellar Court property (excluding \$126,000 of unamortized debt premium).

In connection with the acquisition of certain properties by PREI II LLC in April 2007, it assumed an obligation related to the remediation of environmental conditions at off-site parcels located in Cambridge, Massachusetts. PREI II LLC has estimated the cost of the remediation to be \$3.6 million, which was recognized at the time of acquisition as an increase to the assets acquired and the recognition of a corresponding liability, in accordance with the guidance provided in SFAS No. 143, *Accounting for Asset Retirement Obligations*.

Table of Contents**Cash Distribution Policy**

We elected to be taxed as a REIT under the Code commencing with our taxable year ended December 31, 2004. To qualify as a REIT, we must meet a number of organizational and operational requirements, including the requirement that we distribute currently at least 90% of our ordinary taxable income to our stockholders. It is our intention to comply with these requirements and maintain our REIT status. As a REIT, we generally will not be subject to corporate federal, state or local income taxes on taxable income we distribute currently (in accordance with the Code and applicable regulations) to our stockholders. If we fail to qualify as a REIT in any taxable year, we will be subject to federal, state and local income taxes at regular corporate rates and may not be able to qualify as a REIT for subsequent tax years. Even if we qualify as a REIT for federal income tax purposes, we may be subject to certain state and local taxes on our income and to federal income and excise taxes on our undistributed taxable income, *i.e.*, taxable income not distributed in the amounts and in the time frames prescribed by the Code and applicable regulations thereunder.

The following table provides historical dividend information for our common and preferred stock for the prior two fiscal years and the nine months ended September 30, 2008:

Quarter Ended	Date Declared	Date Paid	Dividend per Common Share	Dividend per Preferred Share
March 31, 2006	February 27, 2006	April 17, 2006	\$ 0.2900	\$
June 30, 2006	May 19, 2006	July 17, 2006	0.2900	
September 30, 2006	September 14, 2006	October 16, 2006	0.2900	
December 31, 2006	December 13, 2006	January 16, 2007	0.2900	
March 31, 2007	March 15, 2007	April 16, 2007	0.3100	0.45582
June 30, 2007	June 15, 2007	July 16, 2007	0.3100	0.45582
September 30, 2007	September 14, 2007	October 15, 2007	0.3100	0.46094
December 31, 2007	December 12, 2007	January 15, 2008	0.3100	0.46094
March 31, 2008	March 14, 2008	April 15, 2008	0.3350	0.46094
June 30, 2008	June 16, 2008	July 15, 2008	0.3350	0.46094
September 30, 2008	September 15, 2008	October 15, 2008	0.3350	0.46094

Inflation

Some of our leases contain provisions designed to mitigate the adverse impact of inflation. These provisions generally increase rental rates during the terms of the leases either at fixed rates or indexed escalations (based on the Consumer Price Index or other measures). We may be adversely impacted by inflation on the leases that do not contain indexed escalation provisions. In addition, most of our leases require the tenant to pay an allocable share of operating expenses, including common area maintenance costs, real estate taxes and insurance. This may reduce our exposure to increases in costs and operating expenses resulting from inflation, assuming our properties remain leased and tenants fulfill their obligations to reimburse us for such expenses.

Portions of our unsecured line of credit and secured construction loan bear interest at a variable-rate, which will be influenced by changes in short-term interest rates, and will be sensitive to inflation.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our future income, cash flows and fair-values relevant to financial instruments depend upon prevailing market interest rates. Market risk is the exposure to loss resulting from changes in interest rates, foreign currency exchange rates, commodity prices and equity prices. The primary market risk to which we believe we are exposed is interest rate risk. Many factors, including governmental monetary and tax policies, domestic and international economic and

political considerations and other factors that are beyond our control contribute to interest rate risk.

As of September 30, 2008, our consolidated debt consisted of the following (dollars in thousands):

	Debt Summary (1)	Percent of Total Debt	Effective Interest Rate at End of Quarter
Fixed interest rate (2)	\$ 529,828	34.2%	5.17%
Variable interest rate (3)	1,017,658	65.8%	5.45%
Total/effective interest rate	\$ 1,547,486	100.0%	5.35%

(1) Debt summary includes only consolidated indebtedness.

(2) Includes 13 mortgage notes payable secured by certain of our properties (including \$9.3 million of unamortized premium) and our exchangeable senior notes.

(3) Includes our unsecured line of credit, secured term loan, and secured construction loan, which bear interest based on a LIBOR-indexed variable interest rate, plus a credit spread. However, we are party to two interest rate swaps, which were intended to have the effect of initially fixing

the interest rates on \$150.0 million of our unsecured line of credit at 5.9%. We have also entered into an interest rate swap agreement that is intended to fix the interest rate on the entire \$250.0 million outstanding balance of the secured term loan at a rate of 5.8% until the interest rate swap expires in 2010. We have also entered into four forward starting swap agreements, which are intended to have the effect of fixing the interest rate on \$450.0 million of forecasted debt issuance (after retirement of the secured construction loan) at approximately 5.2%. At September 30, 2008, the total amount of unhedged variable-rate debt was approximately \$617.7 million, with an effective weighted average interest rate of 4.3%.

Table of Contents

To determine the fair-value of our outstanding indebtedness, the fixed-rate debt is discounted at a rate based on an estimate of current lending rates, assuming the debt is outstanding through maturity and considering the notes collateral. At September 30, 2008, the fair-value of the fixed-rate debt was estimated to be \$492.8 million compared to the net carrying value of \$529.8 million (includes \$9.3 million of unamortized premium). We do not believe that the interest rate risk represented by our fixed-rate debt was material as of September 30, 2008 in relation to total assets of \$3.2 billion and equity market capitalization of \$2.2 billion of our common stock, operating partnership and LTIP units, and preferred stock. At September 30, 2008, the fair-value of the debt of our investment in unconsolidated partnerships approximated the carrying value.

Based on the outstanding unhedged balances of our unsecured line of credit, secured construction loan, and secured term loan and our proportionate share of the outstanding balances for the PREI limited liability companies secured acquisition loan and secured construction loan at September 30, 2008, a 1% change in interest rates would change our interest cost by approximately \$6.9 million per year. This amount was determined by considering the impact of hypothetical interest rates on our financial instruments. This analysis does not consider the effect of any change in overall economic activity that could occur in that environment. Further, in the event of a change of the magnitude discussed above, we may take actions to further mitigate our exposure to the change. However, due to the uncertainty of the specific actions that would be taken and their possible effects, this analysis assumes no changes in our financial structure.

In order to modify and manage the interest rate characteristics of our outstanding debt and to limit the effects of interest rate risks on our operations, we may utilize a variety of financial instruments, including interest rate swaps, caps and treasury locks in order to mitigate our interest rate risk on a related financial instrument. The use of these types of instruments to hedge our exposure to changes in interest rates carries additional risks, including counterparty credit risk, the enforceability of hedging contracts and the risk that unanticipated and significant changes in interest rates will cause a significant loss of basis in the contract. To limit counterparty credit risk we will seek to enter into such agreements with major financial institutions with high credit ratings. There can be no assurance that we will be able to adequately protect against the foregoing risks and will ultimately realize an economic benefit that exceeds the related amounts incurred in connection with engaging in such hedging activities. We do not enter into such contracts for speculative or trading purposes.

ITEM 4. CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Also, we have investments in unconsolidated entities. As we manage these entities, our disclosure controls and procedures with respect to such entities are essentially consistent with those we maintain with respect to our consolidated entities.

As required by Securities and Exchange Commission Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

There has been no change in our internal control over financial reporting during the quarter ended September 30, 2008 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Although we are involved in legal proceedings arising in the ordinary course of business, we are not currently a party to any legal proceedings nor, to our knowledge, is any legal proceeding threatened against us that we believe would have a material adverse effect on our financial position, results of operations or liquidity.

ITEM 1A. RISK FACTORS

There are no material changes to the risk factors described under Part I, Item 1A, Risk Factors, in our annual report on Form 10-K for the year ended December 31, 2007. Please refer to that section for disclosures regarding the risks and uncertainties related to our business.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5. OTHER INFORMATION

Our board of directors amended and restated the company's bylaws effective October 29, 2008. The following sets forth a summary of the amendments to the bylaws, which is qualified in its entirety by reference to the company's Second Amended and Restated Bylaws filed as Exhibit 3.1 hereto and incorporated by reference in this item.

General

In addition to the amendments described below, the amended bylaws include certain changes to (1) clarify language and (2) make various technical corrections and non-substantive changes.

Article II Meetings of Stockholders

Section 3. Special Meetings. Under the amended bylaws, a special meeting of the stockholders is required to be called upon the written request of stockholders representing a majority, rather than one-fourth, of the votes entitled to be cast at such meeting.

Section 4. Notice. The amended bylaws permit a single notice to be effective for all stockholders sharing the same address. Additionally, the amended bylaws clarify that imperfect notice to one or more stockholders will not affect the validity of an annual meeting or a special meeting of stockholders and that the company can postpone or cancel a meeting of the stockholders by making a public announcement prior to the meeting.

Table of Contents

Section 10. Inspectors. The amended bylaws provide that the board of directors or the chair of the meeting of stockholders may appoint, before or at the meeting, one or more inspectors. Additionally, the inspector's authority and responsibilities are clarified.

Section 11. Advance Notice of Stockholder Nominees for Director and Other Stockholder Proposals. The amended bylaws require stockholders to submit notice of director nominations or other business proposals to the company's secretary not earlier than the 150th day nor later than 5 p.m., Pacific Time, on the 120th day prior to the first anniversary of the date of the proxy statement for the preceding year's annual meeting of stockholders. The former bylaws required that such notice be given not less than 90 days nor more than 120 days prior to the first anniversary of the mailing of notice for the preceding year's annual meeting of stockholders. In addition, the amended bylaws (a) enhance the requirements relating to information that a stockholder submitting notice of director nominations or other business proposals must provide, including information about persons acting in concert with such stockholder proponent, (b) enhance other informational requirements, including information about hedging activities and investment strategies with respect to the stockholder proponent's investment in the company and in affiliated entities, and (c) establish procedures for the verification of information provided by the stockholder proponent.

Article III Directors

Section 15. Reliance. The amended bylaws conform the provision regarding reliance by directors on others to more closely track Maryland law.

Section 16. Ratification. The amended bylaws clarify the power of the board of directors or the stockholders to ratify any action or inaction that they could have originally authorized, including any action or inaction questioned in derivative proceedings or other matters.

Article V Officers

Section 11. Treasurer. The amended bylaws, consistent with the company's current practice, eliminate the requirement that the treasurer provide the company a bond at the discretion of the board of directors for the performance of his or her duties.

Section 12. Assistant Secretaries and Assistant Treasurers. The amended bylaws, consistent with the company's current practice, eliminate the requirement that the assistant treasurer provide the company a bond at the discretion of the board of directors for the performance of his or her duties.

Article VII Stock

Section 1. Certificates. The amended bylaws, consistent with the New York Stock Exchange Direct Registration System rules, clarify that the company's securities may be issued without certificates and that stockholders are not entitled to physical certificates.

Section 2. Transfers. The amended bylaws, consistent with the New York Stock Exchange Direct Registration System rules, clarify that the company's securities may be issued without certificates.

Section 3. Replacement Certificate. The amended bylaws, consistent with the New York Stock Exchange Direct Registration System rules, clarify that the company's securities may be issued without certificates and that stockholders are not entitled to physical certificates.

Section 4. Fixing of Record Date. The amended bylaws revise requirements for setting of a record date to reflect standard company practice by deleting references to closing of the transfer books in lieu of setting a record date.

ITEM 6. EXHIBITS

Exhibit Number	Description of Exhibit
3.1	Second Amended and Restated Bylaws of BioMed Realty Trust, Inc.
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

36

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BioMed Realty Trust, Inc.

/s/ ALAN D. GOLD

Alan D. Gold Chairman of the Board,
President and Chief Executive Officer
(Principal Executive Officer)

/s/ KENT GRIFFIN

Kent Griffin
Chief Financial Officer
(Principal Financial Officer)

Dated: October 30, 2008

37

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
3.1	Second Amended and Restated Bylaws of BioMed Realty Trust, Inc.
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.